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ABSTRACT 
 
THE PREPARATION AND STUDY OF LIPOPHILIC S-NITROSOTHIOLS FOR IMPROVING 
THE BIOCOMPATIBILITY OF MEDICAL GRADE POLYMERS 
by 
Alex R. Ketchum 
 
 
Chair: Mark E. Meyerhoff 
Advances in biomaterials, polymer science, and biotechnology have resulted in the 
development and implementation of a wide array of implantable biomedical devices and 
drug/device combination products such as catheters, drug-eluting stents, and artificial organs. 
Unfortunately, inserting a foreign material into the body can cause undesirable effects, the 
nature of which depends upon the device’s biocompatibility with blood or tissue.  Common 
complications resulting from the use of implantable biomedical devices include cellular 
proliferation, thrombosis, and the increased risk of infection.  The work described in this thesis 
aims to develop novel lipophilic S-nitrosothiols (RSNOs) that, when incorporated into polymers, 
provide nitric oxide (NO) release capable of greatly improving the material’s biocompatibility.
 
xviii 
 
Initial studies focused on developing methodologies to synthesize fourteen lipophilic 
RSNOs with LogP values ranging from 1.7 to 10.8.  Of these, S-nitroso-tert-dodecylmercaptan 
(SNTDM) and S-nitrosotriphenylmethanethiol (SNTPMT) exhibited the most promising stability 
for potential practical use in polymeric materials.  Silicone rubber (SR), Elasteon-E2As (E2As), and 
CarboSil (CS) films containing 10 wt% SNTDM released NO at physiological levels for 
approximately one month.  SR and CS films containing 10 wt% SNTPMT released NO at 
physiological levels for 41 d, while SNTPMT in E2As lasted 33 d. SNTDM and SNTPMT leached 
minimally from SR (2.4 ± 0.4%, 2.0 ± 0.2%), CS (3.1 ± 0.5%, 1.8 ± 0.3%), and E2As (2.3 ± 0.4%, 1.5 
± 0.3%).  An LDH assay was used to measure the relative amounts of platelets adhered to 
polymers doped with the different RSNOs.  SNTDM and SNTPMT demonstrated excellent 
antiplatelet activity by reducing levels on SR (3.0 ± 0.3%, 8.6 ± 0.1%), CS (12.3 ± 2.0%, 22.1 ± 5.9%) 
and E2As (14.0 ± 3.4%, 23.8 ± 6.2%) relative to the controls.  A solvent swelling method was 
developed to impregnate SNTDM in SR catheters which released NO at or above physiological 
levels for ~26 d.  The catheters were incubated in a CDC bioreactor containing S. aureus for 21 d 
and killed or inhibited growth of 99.9% of the bacteria.  Polymer films containing SNTDM 
demonstrated substantial photoinduced NO release, more than an order of magnitude greater 
than any RSNO previously tested in the literature.
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CHAPTER 1. 
INTRODUCTION 
 
1.1 Health Concerns Associated with the Use of Implantable Medical Devices  
Current health care employs a vast array of biomedical devices that are used for a range 
of state-of-the-art medical procedures.  Despite their widespread use, current-generation 
implantable devices without special mitigation strategies are extremely susceptible to 
thrombosis and infection, decreasing their functional lifetimes and increasing risk associated with 
their use.1–3 Catheters, one of the most fundamental biomedical devices, have gastrointestinal, 
neurovascular, cardiovascular, and urological applications, to name only a few.4  For example, 
during hemodialysis (HD), a common treatment for those suffering from kidney failure, 
intravascular (IV) catheters carry blood to and from the patient via an extracorporeal 
circuit/filtration unit with a selective membrane to remove waste species (e.g., urea), restore the 
proper balance of electrolytes, and eliminate extra fluid from the blood, all tasks normally 
performed by healthy functioning kidneys.5,6  Bladder catheterization, another ubiquitous 
application, also involves implantable catheters to drain the bladder into recipient bags, although 
the procedure is not intravascular.7  Despite the high frequency in performance of these 
procedures, serious health complications are very common in both IV and urinary catheters due 
to the risks associated with introducing foreign bacteria into the body,3 and in the case of IV 
catheters, also enhancing the risk of blood clot formation.2,8   
Catheters are fabricated from polymeric materials; therefore, it is the nature of these 
polymers, especially at the catheter surfaces, that directly influence the devices’ 
biocompatibilities.4,9,10  The term “biocompatibility” has a broad definition, but in this instance,
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it usually refers to a biomaterial’s ability to perform its intended function without eliciting 
undesirable effects in a patient.11,12  In the case of IV catheters, this can be due to a host response 
(discussed below),1 or as is the case with urinary and IV catheters, the increased risk of microbial 
infection.9  Table 1.1 (below) lists common biomedical devices and polymeric materials, as well 
as the health concerns resulting from their use. 
Implantable medical devices such as venous access ports can provide many benefits for 
patients undergoing frequent blood-sampling, blood transfusion, or IV drug delivery such as in 
chemotherapy and hemodialysis, respectively.13–15  However, placement of these intravenous 
ports induces a “foreign body response,” increasing risks to patients.9  A common host response 
to a blood-contacting polymer is as follows: during the early process of intravenous device 
implantation, blood/material interactions cause proteins such as von Willebrand Factor (vWF) 
and fibrinogen to adsorb to the polymer’s surface and a blood-based transient matrix forms on 
the device.9,16–19  If there is tissue trauma during device implantation, a complex wound healing 
cascade will also ensue.  Acute inflammation occurs during initial implantation and can last on 
the order of a few days, during which increased blood flow cleans the area and initiates clot 
formation through activation of the coagulation cascade pathways.  Cytokines and growth factors 
are released, and leukocytes adhere to the blood vessel’s endothelium at the site of trauma.  
Longer-term implantation can lead to chronic inflammation increasing macrophage, lymphocyte, 
Table 1.1 Implantable biomedical devices, common biomaterials they are composed of or coated with, as well 
as health concerns associated with their use. 
Biomedical Devices Common Biomaterials Biocompatibility Concerns
Catheters Silicone rubber Thrombosis
Stents Polyurethanes Infection
Pacemakers Polycarbonates Cellular proliferation
Intravascular sensors Poly (vinyl chlorides) Device malfunction
Shunts Polyethylene glycol Toxicity
Orthopedic implants Polytetrafluoroethylene Endothelial damage
Breast implants Polypropylene
Drug delivery devices Chitosan
surgical sutures Polystyrene
Heart valves Polyesters
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and leukocyte levels.19  Blood vessels proliferate and connective tissue begins to restructure the 
area.  During this restructuring phase, granulation tissues are formed from the acute 
inflammatory phase’s blood clot.  Growth factors aid in the generation of fibrous tissue and blood 
vessels.  After blood/material interactions, activated platelets and the cells that are within the 
clot release chemoattractants that recruit and direct macrophages to the site of injury.  
Macrophages adhered to the biomaterial surface and fuse to form foreign body giant cells.9  This 
provides a microenvironment which is especially conducive to device degradation.  For example, 
when used in artificial joints, polyethylene’s surface is oxidized from extended contact with the 
radical oxygen species produced in the foreign body giant cells’ microenvironment.9,20  
Additionally, similar oxidative processes cause damage to pacemaker leads, rendering them 
brittle and susceptible to cracking and device failure over time.9  
The inflammatory response resulting from endothelial trauma with device implantation 
is also associated with the migration of vascular smooth muscle cells.  This can thicken arterial 
walls and result in neointimal hyperplasia.  This is observed with polytetrafluoroethylene (PTFE) 
coated wire conduits during hemodialysis.6,9,16,20  
Thrombosis is a serious concern with any blood contacting device such as stents, 
catheters, extracorporeal circuits, etc.  Thrombosis can occur due to a damaged endothelium, 
which often happens during implantation of coronary stents; this results in the exposure of 
subendothelial matrix.  Most applicable to this dissertation, clot formation on the polymer 
surface of IV catheters can occlude blood or fluid flow through the lumen(s).  Following device 
implantation, a complex cascade of events takes place (see Fig. 1.1).  Plasma proteins, such as 
von Willebrand Factor (vWF) and fibronectin/fibrinogen, are adsorbed on the polymer within 
minutes of blood contact, and are immediately available to activate circulating platelets and 
recruit them to the polymer surface.  This causes a conformational change, exposing a fibrinogen 
binding-receptor (a glycoprotein) that is later enzymatically converted to fibrin via thrombin.  
Platelet aggregation ensues as fibrin forms a cross-linked insoluble network or blood clot.  Clots 
can further impede device function as well as detach and cause an emobolism.2,8,9,16,19,21   
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Another health concern with implanted biomedical devices is the increased risk of patient 
infection.  Although, several different sterilization techniques are commonly used, foreign 
devices can still carry pathogens, which are inevitably present (including on the skin of patients), 
particularly in high-exposure environments such as hospitals.  Further bacteria can enter the 
body by moving along the surface of the device (e.g., IV catheter).22,23  Bacteria, which may start 
as free-floating planktonic cells, excrete extracellular polymeric substances (EPS) which form 
environmentally-resistant biofilms on foreign surfaces, such as catheters.  Bacteria present within 
a biofilm exhibit antibiotic resistance due to adaptive stress responses and poor antibiotic 
penetration, as well as protection from the host’s immune system (see Fig. 1.2).  In fact, biofilms 
older than 7 d, require 1000-5000 times the concentration of antibiotics required to kill the same 
species of planktonic cells.22,24–26   
In addition to the resistance to the host immune response and antibiotic drug treatment, 
biofilms also often impact a device’s intended function.  Consequently, devices require frequent 
replacement.  This increases medical costs to hospitals and insurance companies, and triggers 
the harmful effects associated with frequent implantation (e.g., endothelial damage).  Although 
progress has been made in preventing catheter-related bloodstream infections (CRBIs), 
complications remain prevalent and are estimated to cost between $670 million and $2.68 billion 
USD annually just in the United States alone.  More importantly, CRBIs cause >25,000 deaths each 
Figure 1.1 Thrombus formation on the polymeric surface of a biomedical device, e.g. intravenous 
catheter.  (a) A newly implanted biomaterial’s surface is rapidly covered with (b) adsorbed proteins, 
such as vWF, which then (c) activate circulating platelets, causing them to attach and expose fibrin 
binding sites. (d) Platelet aggregation proceeds as fibrin forms a cross-linked network. 
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year in U.S. Hospitals.  Further, urinary tract infections (UTIs) are also very commonly associated 
with use of urinary catheters, accounting for a 75% infection rate for catheters placed 
chronically.24,27   
Many types of biomaterials are used for fabricating biomedical devices, several of which 
are listed earlier in Table 1.1.  Rarely do biomaterials alone address all areas that cause 
biocompatibility issues.4,11,12,19,28  Polyesters, the most common biodegradable polymer, are 
commonly used for drug-delivery systems and orthopedic devices (e.g., pins and rods); however, 
studies have shown their decomposition results in the accumulation of acidic degradation 
byproducts, triggering local inflammation or systemic reactions.4,12,28,29  In addition to preventing 
the direct biocompatible health concerns discussed above, biomaterials must possess 
appropriate physical characteristics and exhibit minimal toxicity from chemical leaching or 
degradation.  For example, although poly(vinyl chloride), or PVC, is one of the most common 
biomaterials, it requires the addition of phthalate plasticizers to impart soft and flexible physical 
properties.4  This compound was discovered to induce acute inflammation in patients and as well 
 
Stage 3: Maturation I Stage 4: Detachment Stage 2: EPS production Stage 1: Attachment            
Planktonic  
bacteria 
Stage 5: Dispersion 
Figure 1.2. Biofilm formation on the polymeric surface of a biomedical device. 1) Planktonic bacteria attach to 
the foreign surface as mediated by cell surface adhesins and (2) release EPS to form a base film.  (3) A 
microcolony develops, and the biofilms mature as mediated by cell-signaling molecules.  (4) Finally, bacteria 
are released to further colonize surfaces and spread systemically. 
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as liver toxicity in animals.  Following a Public Health Notification by the US FDA in 2002, this 
polymer system is being replaced with other polymeric biomaterials.4   
Polyurethane derivatives (PU) and silicone rubbers (SR) are the primary focus of this 
dissertation as they are two of the most common clinically-used polymers for preparing typical 
biomedical devices and possess hydrophobic character (i.e., lower water uptake).4,30  Despite 
their frequency of use, PU and SR remain plagued by thrombosis and biofilm formation 
issues.9,11,16  The target bioactive species for incorporation into such devices, lipophilic S-
nitrosothiols (RSNOs) (discussed in detail within Section 1.3), are hypothesized to display 
increased retention (minimal leaching) within certain PU and SR materials given their common 
non-polar environments,31 imparting additional biocompatibility to the materials in which they 
are loaded.  Devices made with PU and SR are discussed in more detail within Chapters 2 and 4.  
 
1.2 Recent and Current Efforts to Improve the Biocompatibility of Medical Devices 
Considerable research has attempted to increase the biocompatibility of biomedical 
devices.  Although progress has been made on several strategic fronts, the use of implantable 
devices remains associated with higher risk of the aforementioned health-concerns.  Heparin, an 
anticoagulant medication, is frequently injected into patients to prevent thrombosis during 
hemodialysis and unwanted clotting during open-heart surgery.  Unfortunately, the heparin 
treatments can induce thrombocytopenia, or a decreased number of platelets, and thus carry an 
increased risk of hemorrhage.32–34  Drugs administered to prevent bacterial infection and biofilm 
formation during procedures such as urinary catheterization exhibit significantly decreased 
potency given the biofilm’s protective effects.24,26  The use of antibiotics can result in undesirable 
side-effects and facilitate the growth of drug-resistant bacteria.35    
Certain biomaterials/polymers exhibit some degree of biocompatibility; however, it is 
often insufficient to adequately prevent the common health concerns.  Each polymer possesses 
unique properties causing certain polymers to have increased biocompatibility for specific 
applications, but often insufficient or reduced biocompatibility for others.10,4,6,11  Researchers 
have reported trends showing that polymers mimicking the endothelium are less prone to the 
foreign body response.9,36,37  By covalently modifying the surface, or through the use of passive 
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and active coatings, scientists have been able to increase device biocompatibility.  For example, 
wire coatings made from PTFE exhibit reduced transient electron distributions due to the 
polymer’s carbon-fluorine bonds.  This results in less Van der Waals interactions with proteins, 
and decreased thrombogenicity; however, its low coefficient of friction correlates with wire 
slippage and arterial perforation.38,39  Biomedical devices have exhibited reduced biofilm 
formation and infection resulting from protein and microorganisms via use of repellent coatings.  
Polymeric brush coatings, such as polyethylene glycol (PEG), have also been shown to reduce 
biofilm and bacterial adhesion.  Water molecules hydrate the surface due to PEG’s hydrophilic 
character and form a steric barrier.40–43  Unfortunately, this brush coating is chemically unstable 
and there is little control over the quality of the monolayer.9,16,44  
In addition to surface modification, drug-eluting biomedical devices are a growing and 
promising area of research; however, each has their own advantages and disadvantages.  Drug-
releasing biomaterials aim to enhance the polymer’s healing or antimicrobial properties through 
the controlled release of active pharmaceutical ingredients to the surrounding tissue or blood 
stream.45–48  A number of wound dressings featuring this methodology have been 
commercialized.46  One of the most promising was develop by Suzuki et al.  The reported wound 
dressing releases gentamycin from a poly(vinyl alcohol) derivative when the peptide linker is 
cleaved by a proteinase near P. aeruginosa infections.49 Unfortunately, these temporary 
dressings require frequent changing, which is uncomfortable for the patient and can increase the 
risk of secondary infections.46,47  In another attempt to enhance the biocompatibility of 
commercial medical devices through controlled drug release, Foley urinary catheters have been 
coated with silver salts intended to prevent infections.  Such devices have been commercialized.  
Unfortunately, Ag+ eluting urinary catheters have not solved the problem of infection given that 
The Healthcare Infection Control Practices Advisory Committee (HICPAC) states that silver-alloy 
coated catheters lead to similar infection rates compared to the conventional silicone ones.  
Silver salt coated Foley catheters also significantly increase the cost of this product over typical 
catheters, leaving the door open for the development of less-expensive and longer-lasting 
antimicrobial devices.7,50 
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1.3 Nitric Oxide  
A growing method currently under academic study for improving medical devices’ 
biocompatibility involves the use of nitric oxide (NO).  Since the discovery that NO is produced 
within our body by several enzymes, scientists have learned that NO exhibits a diverse range of 
benefits including potent antimicrobial and antithrombotic properties.51,52,53  Consequently, 
many of NO’s effects on cells and tissues can be used to improve the biocompatibility of medical 
devices.36  In our bodies, NO is catalytically produced from arginine in a wide variety of cells by 
three isoforms of the enzyme nitric oxide synthase (NOS): endothelial (eNOS), neuronal (nNOS), 
and inducible nitric oxide synthase (iNOS).  nNOS and iNOS are soluble and present in the cytosol, 
having roles involved with neuro-signalling and immune defense against pathogens, respectively.  
eNOS is associated with membranes and regulates vascular function and clot formation.52,53,54  
Endothelial cells release NO and prostacyclin to regulate thrombosis by prevention of platelet 
activation and adhesion to the endothelium.  Activated platelets, in turn, release NO to inhibit 
further thrombosis propagation via a negative feedback mechanism.  Following damage to the 
endothelium, prothrombin is converted to thrombin, which increases intracellular Ca2+ levels.  
Within platelets, the increased Ca2+ associates with calmodulin and initiates NO production via 
eNOS.  The produced NO stimulates soluble guanylyl cyclase to produce cyclic GMP, which in turn 
stimulates a cGMP dependent protein kinase that finally reduces fibrinogen binding.17,19,52,53  
Given NO’s ability to prevent platelet adhesion and aggregation, NO-releasing biomedical devices 
have been shown to consistently reduce thrombus formation and minimized risks, such as the 
potential for pulmonary embolism.37,55  
Additionally, NO-releasing biomaterials have repeatedly demonstrated reduced bacteria 
adhesion and biofilm formation compared to controls; consequently, this opens the opportunity 
to utilize such materials to prevent infections associated with implantable devices such as 
catheters.  There are several possible routes and explanations for NO’s antimicrobial activity, 
depending on various factors including, but not limited to, the specific microbe.   DNA is a target 
for reactive nitrogen species.  NO can deaminate DNA, as well as damage it oxidatively by the 
formation of other antimicrobial species such as peroxynitrite.  The additional antimicrobial 
species are formed due to increased levels of superoxide produced during inflammation.  NO has 
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also been observed to inactivate various enzymes containing Fe-S clusters, thus inhibiting their 
metabolic activity and causing cytotoxicity.36,51,52,56,57,58  
In the presence of oxygen, NO rapidly oxidizes to form NO2 via the reaction shown below 
(Reaction 1.1).  NO2 is a toxic species and its generation must be avoided or controlled when 
dealing with biomedical applications.  Within the bloodstream, NO is converted to nitrate by 
reaction with oxyhemoglobin within a few seconds (Reaction 1.2), preventing the accumulation 
of high NO concentrations.  One of the main applications, NO inhalation therapy (INO), has been 
used for many years to provide vasodilation of arteries during respiratory failure without causing 
a systemic effect; however, NO’s short half-life limits its use for any other applications.36,51,52,59   
 
Although gaseous NO’s direct medical applications are limited, NO donors have increased 
stability, and thus can act as controlled, localized sources of NO.  Nitroglycerin (NG) has been 
used for over 130 years to treat heart conditions through the vasodilatory action of NO (see 
Figure 3a).  Although NG is not a NO-donor by the strictest definition, since it requires an 
aldehyde dehydrogenase for the in vivo conversion to NO, it still serves as a stable and 
controllable source of NO.  Physiologically, the body stores its own reservoir of NO as nitrosonium 
groups (N≡O+) bound to the sulfurs in S-nitrosothiols (RSNOs), the class of NO-donors studied in 
this dissertation work (see Figure 1.3c).  Such species have greatly increased stability relative to 
NO itself.36,51,52,59  RSNOs will be discussed further in Section 1.4.  
Various classes of exogenous NO-donors have also been studied as potential NO sources 
for biomedical applications including diazeniumdiolates (NONOates), nitrogen oxides (NOx), and 
metal-nitrosyl compounds (see Figure 1.3a-d).  NONOates have progressed furthest toward 
clinical use, with a NO releasing anti-acne product currently in phase 3 clinical 
trials.31,36,45,59,60,61,62 
One of the most promising applications, and the focus of this dissertation, involves the 
incorporation of NO-donors into polymers, producing NO-releasing biomedical devices.  These 
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biomaterials commonly exhibit superior biocompatibility given NO’s salubrious antithrombotic 
and antimicrobial effects.  Such NO-releasing devices can provide treatment at localized sites, 
thus minimizing side effects and complications accompanying the use of systemic or local 
antibiotics (e.g., drug interactions), especially given the ever-growing rise of antibiotic resistant 
bacteria.  Due to NO’s propensity to oxidize, the biomaterials should release NO in controlled 
amounts, for specific durations, and at discrete locations.2,7,30,63  One target NO-release system 
with incorporated RSNOs is specifically depicted and described in Chapter 2.  
 
1.4 S-Nitrosothiols    
S-Nitrosothiols, or RSNOs, are a class of molecules defined by a nitroso group bound to 
the sulfur of a thiol (see Figure 1.4).  Although the NO synthesized by endothelial cells can diffuse 
randomly to the surrounding environment, RSNOs serve as a physiological NO-donor by providing 
a more stable reservoir of NO, which can be released as needed at discrete locations upon 
exposure to various stimuli.  Endogenous RSNOs include the small molecules S-nitrosocysteine 
(CysNO) and S-nitrosoglutathione (GSNO) (see Figure 1.4), as well as the protein, S-
nitrosoalbumin.52,53,59  
Figure 1.3. Sources of NO for use or potential use in medical applications.  (a) Trinitroglycerin and (b) 
sodium nitroprusside are currently used clinically.  (c) Endogenous S-nitrosothiols serve as NO donors 
and reservoirs, while exogenous species are still in clinical trials.  (d) Ointments with diazeniumdiolate 
based ingredients/species are currently in phase III clinical trials.  
a) 
b) 
c) 
d) 
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Many potential explanations for RSNOs’ biological synthesis have been proposed and it’s 
almost certain that multiple pathways exist.  The dominant pathway involves NO’s reaction with 
oxygen followed by an additional NO molecule to form N2O3, which in turn creates NO2 and NO+, 
the nitrosating agent added to proximal thiols.  Other pathways are circumstantially dependent, 
such as the reaction between peroxynitrite and a thiol, which could occur at locations of 
inflammation given the increased concurrent generation of NO and superoxide.  Synthetically, 
RSNOs can be prepared via the nitrosation of thiols using alkyl or acidified nitrites (see Reaction 
1.3) or via a transnitrosation reaction with a different RSNO (Reaction 1.4).  Finally, RSNOs release 
NO via thermal or photolytic decomposition, or upon exposure to certain metal ions such as Cu(I) 
(see Reaction 1.5).2,59,64  
 
 
 
Given the endogenous RSNOs’ inherent biocompatibility, they have been thoroughly 
studied as a means to create controllable NO delivery from biomaterials and consequently 
increase biocompatibility; however, they have limitations including low stability in the presence 
of certain environmental factors and susceptibility towards thermal and photolytic 
decomposition.30,59,64  These traits make device preparation and storage of RSNOs difficult.36,59 
Figure 1.4. Two endogenous small molecule RSNOs: S-nitrosocysteine and S-nitrosoglutathione, and 
the exogenous species, S-nitroso-N-acetylpenicillamine, have each been extensively studied for use 
as NO donors in biomedical applications. 
rxn 2.3 
rxn 2.5 
rxn 2.4 
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Further, the endogenous RSNOs are highly water soluble, resulting in extraction out of the 
polymeric materials when in contact with blood or urine.  Therefore, various exogenous NO 
donors have been incorporated into biomedical polymers in attempt to utilize NO’s effects, one 
of the most promising being S-nitroso-N-acetylpenicillamine (SNAP) (Figure 1.4).19-21,30,65  Indeed, 
members/collaborators in the Meyerhoff lab recently demonstrated SNAP’s ability to release NO 
over long durations (> 3 weeks) and decrease thrombus formation at localized treatment sites 
when it is doped within biomedical polymers.30  Additionally, Colletta et al. recently reported that 
silicone rubber Foley catheters impregnated with SNAP were able to greatly decrease 
Staphylococcus epidermidis and Proteus mirabilis levels on the surface of the catheters for 2 
weeks relative to controls (in an in vitro bioreactor model).7  One limitation, however, is that an 
appreciable amount of SNAP, and likely the NAP disulfide dimer, leach from the polymers.  
Leaching decreases NO’s efficacy and longevity at the localized polymer site and can cause NO’s 
effects at unintended locations within the body.65  
RSNOs have been covalently bound to the polymer backbone of biomaterials, as well as 
non-covalently dispersed.30,66  Given RSNOs’ inherent instability, device preparation steps 
requiring extended time allocation can cause premature NO release.  While it would be desirable 
to incorporate RSNOs into the polymeric catheters via an extrusion process, RSNOs cannot 
withstand the elevated temperatures required for catheter extrusion.7  Covalently-bound RSNOs 
do not suffer from leaching, but they often require significant preparation time.  In comparison, 
non-covalently dispersed RSNOs can be loaded into a polymer much quicker, although they may 
be more prone to leaching.67,68  RSNOs dissolved in polymer solutions can be cast without the 
need for elevated temperatures.  Additionally, polymers can be solvent swelled in RSNO 
solutions.  After the solvent has evaporated, the catheters are left impregnated with the RSNO 
species.65  This technique allows loading of specific amounts of RSNO (given the soaking solution’s 
original concentration), and was extensively studied in this thesis work with silicone rubber (see 
Chapter 3).   
SNAP has been reported to have log P value (octanol-water partition coefficient) of 0.96, 
meaning that when exposed to comparable volumes of a nonpolar environment (i.e., 
hydrophobic polymer) and a polar environment such as blood or urine, ~10% of the loaded RSNO 
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is leached into the surrounding solution.30  Given that the volume of blood in the body is 
considerably greater than that of the biomaterials used during applications, leaching can become 
a significant problem.  For example, although Seabra et al. improved GSNO’s lifetime by 
dispersing it throughout poly(vinyl alcohol) films. It was found that 90% of the GSNO was released 
during the first 24 h when the material was exposed to physiological conditions.69,70   This 
dissertation aims to address the phenomenon leaching by incorporating lipophilic RSNOs into 
hydrophobic polymers.  Given their shared non-polar character (and minimal aqueous solubility) 
it was hypothesized that lipophilic RSNOs will be better retained in hydrophobic polymers (see 
above and experimental sections of chapters in this thesis for further discussion of the strategy). 
 
 
In addition to leaching, one of the important factors to consider when designing and 
studying RSNOs is their relative NO release stability.  This directly affects the duration of potential 
treatments as well as the practicality of device storage.  One of the defining characteristics of an 
RSNO that affects its stability is the alkyl substitution at the site of the S-nitroso functionality.  It 
has been repeatedly observed that increased alkyl substitution correlates with greater stability 
(see Figure 1.5).59,64  Although this is true, there are many other factors which are not well 
understood that also affect the stability of given RSNO species.  The effects of alkyl substitution 
are noticed with RSNOs bearing similar structures; however, as will be demonstrated throughout 
this dissertation, variations of other functional groups can play a significant role in stability of the 
S-NO bond.  A direct example of this relates to the two physiological small molecule RSNOs.  
Although GSNO and CysNO are both primary RSNOs, GSNO is widely accepted to be much more 
stable than CysNO under most conditions.67,71,72  GSNO contains an additional carboxylic acid and 
multiple amide functionalities.  This also increases the size and molecular weight of the RSNO.  
Figure 1.5. S-Nitrosothiols’ general structure and substitution.  Alkyl substitution is one of the factors 
effecting RSNOs’ stability in terms of NO release. If other factors remain consistent, tertiary RSNOs 
are more stable than secondary, which in turn are more stable than primary RSNOs. 
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While the effects of functional groups between CysNO and GSNO have a larger impact than the 
substitution (both are primary), this trend does not extend to SNAP, which does not have the 
added extensive functionality of GSNO, yet is almost always drastically more stable than the 
other RSNOs under all conditions.   
Other factors affecting the stability of RSNOs include state of matter, molecular weight, 
polarity, steric bulk, and the solvent/polymeric environment.30,36,59,64  Indeed, as will be 
demonstrated throughout this dissertation, different RSNOs are stabilized by certain polymers, 
while others are unaffected or even exhibit decreased stability.30  There are a few explanations 
for this wide range of RSNO behavior.  One hypothesis was proposed recently in which SNAP is 
stabilized in certain polymers such as Elasteon E2As, a polyurethane via formation of 
microcrystals depending on its concentration.7  Data from this dissertation has supported this 
hypothesis in several situations.  For example, if SNAP derivatives with minor modifications affect 
the RSNOs’ ability to crystallize, such derivatives are considerably less stable.  Additionally, SNAP 
dissolved in solution (even containing phosphate buffered saline (PBS) and ethylene diamine 
tetra-acetic acid (EDTA)) is very unstable, while in the solid form it can last indefinitely under 
certain conditions.30,73  While some RSNOs are labeled as possessing superior stability, 
researchers often fail to recognize that the stability depends on the stimulus that causes 
decomposition.73  Consequently, this dissertation research aims to understand the newly 
prepared RSNOs’ behavior in a variety of environments and conditions.  
Stimuli/Environmental Factors RSNO Traits 
Light Sterics 
Heat Substitution 
Cu(I) Intramolecular SNO proximity 
Solvent Polarity (intemolecular dipole-dipole) 
Polymer Chelating functional groups 
Concentration Electron withdrawing and donating groups 
 
Table 1.2. Many factors affect an RSNOs’ stability including environmental factors and traits that 
are specific to the RSNO 
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While RSNOs’ stability is often a concern, and stimuli need to be avoided, applications 
which desire a sudden off/on NO release can benefit from photolytic cleavage of RSNOs.  
Exposing RSNOs to controlled light sources and specific wavelengths can provide a way to release 
NO at a desired flux and duration.74  Throughout this dissertation, the photoactivity of many of 
the new RSNOs prepared was evaluated for potential use in related applications.  Incorporating 
a catalyst into or onto biomaterials has been explored as a method to facilitate NO release.  
Previous work from the Meyerhoff group demonstrated that poly(vinyl chloride) containing a 
copper(II) cyclen analog was able to catalytically increase the natural NO release from the 
endogenous RSNOs.75 
 
1.5 Summary 
Despite the widespread use of polymeric devices for modern medical procedures, serious 
health complications commonly occur as a result of the inherent limitations of the materials used.  
Enhancement of biomedical device surfaces or compositional materials with NO’s dual 
antiplatelet and antimicrobial properties offers the potential to address many of these concerns, 
extending the lifetime of functionality of the devices.  Progress has been made towards 
developing NO-releasing biomedical devices via the incorporation of NO-donors; however, 
several factors have hindered greater progress.  Factors include small molecule leaching, stability, 
and control over the NO release levels and duration.   
 
Research Statement 
The aim of the research reported in this dissertation is to study novel RSNOs, in and out 
of polymers, to determine their behavior with regard to potentially improving the 
biocompatibility of biomedical devices.  The results from this work contributes to the ever-
growing body of scientific knowledge regarding NO donors and their behavior in various 
environments.  Specific goals throughout the thesis are to: 1) understand the behavior and 
performance of a wide range of RSNOs—including novel species; 2) develop RSNO/polymer 
systems that utilize NO’s antiplatelet and antimicrobial properties to decrease platelet adhesion 
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and/or prevent the risk of infection; and 3) create such RSNO doped polymers systems that 
exhibit, long-term NO-release, minimal leaching, and substantial stability. 
In Chapter 2, a wide range of lipophilic RSNOs—the majority of which are novel—are 
prepared and studied.  The RSNOs were screened for the effects of various stimuli such as light 
and heat on their NO release while in the neat state, in solution, and within polymeric phases. 
These RSNO species were kept in environments with varying temperatures and light exposures 
to determine their storage stability.  The RSNO/polymer systems exhibiting superior stability 
were then tested for leaching and their long-term NO release under physiological conditions. 
Finally, the stable RSNOs with optimized polymeric retention systems were tested for their ability 
to prevent platelet adhesion.  
Chapter 3 focuses specifically on S-nitroso-t-dodecylmercaptan (SNTDM), one of the most 
promising RSNOs examined in Chapter 2.  The behavior of SNTDM was studied in great detail 
under a wide array of conditions in response to several stimuli.  Its leaching from several polymers 
when incorporated at varying concentrations was examined.  Further, a swelling impregnation 
method was developed to incorporate SNTDM into PDMS catheters at various concentrations.  
SNTDM’s photo-induced NO release in SR was studied as well, and is shown to be promising for 
potential photodynamic therapy.  Lastly, the antimicrobial activity of NO releasing SR catheters 
containing SNTDM were tested against S. aureus by observing the bacterial killing effects and 
inhibition of biofilm formation.  Much of this work was published in the Journal of Material’s 
Chemistry B (2016,4, 422-430).  
In Chapter 4, the most stable RSNOs, and polymers in which they were best retained, 
were further studied with respect to their photo-induced NO release.  Research was aimed at 
developing a source of NO that possesses adequate photosensitivity for a controllable 
photoactivated NO release, but does not lose NO at undesirable times.  While SNAP and SNTPMT 
are both fairly stable in response to light, SNTDM exhibited an unprecedented photosensitivity, 
with dramatic differences between the NO release in the dark, with ambient light, and upon 
exposure to a halogen bulb. 
Chapter 5 summarizes the conclusions drawn from the research reported in this 
dissertation as well as provides future directions for further developing and understanding the 
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RSNO/polymer systems that were studied.  Potential applications of the new molecules reported 
are proposed, and based upon the findings from this work, additional potentially useful RSNOs 
are suggested for future preparation and study.  Appendix A contains a devised undergraduate 
organic laboratory experiment, written with my esteemed colleague, Dr. Alexander Wolf, and 
includes results that are similar to what students should obtain.   
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 CHAPTER 2. 
THE SYNTHESIS AND STUDY OF LIPOPHILIC ALKYL AND ARYL S-NITROSOTHIOLS 
 
2.1 Introduction 
As discussed in Chapter 1, considerable research has focused on improving the 
biocompatibility of medical devices by preventing thrombosis and reducing the risk of infection.  
Nitric oxide donors such as S-nitrosothiols have demonstrated the potential to do so.1,2  The most 
commonly studied small molecule RSNOs are the synthetic species S-nitroso-N-
acetylpencillamine (SNAP) and the physiological species, S-nitrosocysteine (CysNO) and S-
nitrosoglutathione (GSNO).  These three RSNOs are inherently biocompatible, but their 
applications have been limited in several ways.3  CysNO and GSNO are both primary RSNOs, which 
limits their stability since alkyl substitution has repeatedly been demonstrated as a major factor 
affecting the rate of NO-release.4  SNAP, a tertiary RSNO, is considerably more stable and 
consequently better suited for biomedical device preparation and storage.  SNAP, CySNO, and 
GSNO are all hydrophilic, which is partially responsible for their decreased retention within 
polymers when exposed to aqueous solutions (leaching).5,6  Given the unique NO release profiles 
of different RSNOs (as well as other NO-donors), considerable research has focused on adding to 
the library of NO releasing compounds for understanding their behavior and potential medical 
applications. 
The Meyerhoff research group has determined that SNAP’s stability can be increased by 
incorporating it into different biomedical grade polymers such as Elasteon-E2As (E2As), CarboSil 
(CS), and silicone rubber (SR).7   SNAP is retained in these hydrophobic polymers more so than in 
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hydrophilic ones such as Tecoflex SG-80A (TF), likely due to their reduced water uptake.7 
However, leaching of these NO donors is still a significant concern and this reduces the duration
of device use.  Also these devices can excrete the disulfide of SNAP, the byproduct of NO release, 
into the body.   
Given the relationship between a molecule’s polarity and preference to retain in an 
environment of similar polarity, research in this chapter is focused on preparing and studying a 
variety of lipophilic RSNOs without other functional groups.  Throughout this chapter a range of 
lipophilic RSNOs will be discussed with regard to their performance in environments relevant to 
biomedical applications.  The RSNOs pertinent to this chapter are listed in Table 2.1 with their 
corresponding LogP values (log octanol/water partition coefficient).  Their Lewis structures are 
depicted in each corresponding section.  Leaching values are compared with SNAP’s in certain 
polymers as well.  The effects of SNAP’s LogP on leaching is discussed in further detail below. 
Alkyl RSNO % RSNO LogP RSNO w/Additional Funct. Groups % RSNO LogP 
S-nitroso-t-butylthiol (SNTBT) 90.4 ± 7.1 1.7 S-nitrosoglutathione (GSNO) 100 -3.2 
S-nitrosohexanethiol (SNHT) 82.3 ± 0.9 3.1 S-nitroso-N-acetylpenicillamine (SNAP) 100 0 
S-nitroso-2-ethylhexanethiol (SNEHT) 72 4.1 S-nitrosocholesterolthiol (SNCT) 8.1 ± 6.4 10.8 
S-nitrosooctanethiol (SNOT) 79.2 ± 3.3 4.2 
S-nitroso-triphenylmethanethiol 
(SNTPMT) 
99.0 ± 3.8 5 
S-nitrosodecanethiol (SNDT) 90.1 ± 4.2 5.3 S-nitrosobenzenethiol (SNBzT) ? 1.9 
S-nitroso-t-dodecanemercaptan 
(SNTDM) 
98.4 ±2.9 6 S,S-dinitrosolipoic acid (SSDNLA) ? 2.4 
S-nitrosododecanethiol (SNDDT) 96 ± 7.0 6.3      
S-nitrosohexadecanethiol (SNHDT) 8.0 ± 5.1 8.4      
S-nitrosooctadecanethiol (SNODT) 5.3 10      
 
Reducing leaching is important since NO’s inherent instability limits its utility to localized 
treatments.  NO is oxidized in the presence of oxygen to form nitrogen dioxide (NO2), which is 
toxic.  Additionally, as occurs in the blood, NO is rapidly consumed by oxyhemoglobin, forming 
methemoglobin—thus deactivating it for any beneficial reactions.8  Due to its reactivity, NO 
should be released from biomedical devices in controlled amounts, for specific durations, and at 
discrete locations.  RSNOs are considerably more stable than NO itself; however, they decompose 
Table 2.1 RSNOs prepared in this chapter, the percentage yields obtained following synthesis, and 
their corresponding LogP values. n=3 for RSNOs with a standard deviations indicated.  
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to release NO under thermal and photolytic conditions.  Consequently, minimizing leaching can 
greatly increase a device’s efficacy. 
Most of the lipophilic alkyl RSNOs studied in this dissertation have seen little to no use for 
biomedical applications.  RSNOs’ stability regarding NO release is not fully understood in many 
instances and as a result, is attributable to factors beyond those commonly considered.  The 
RSNOs examined here are relatively simple, with minimal additional functional groups.  Initially, 
this was hypothesized to form a direct trend: the higher the alkyl substitution, the longer the 
duration of NO release.  Different biomedical applications can benefit from unique durations of 
NO release, and the goal here was to correlate NO release duration with structure, to provide a 
continuum of NO release times.  For example, long-term NO-releasing catheters would be 
applicable for indwelling urinary catheterization since they are often required for several weeks 
or longer.3  Procedures such as angioplasty could benefit from NO-releasing balloons designed to 
release NO on the timescale of only a few hours.  The inherent stability of an RSNO manifests in 
several ways including the duration of NO release and response to the three principle stimuli for 
decomposition (heat, light, and Cu(I)).  Also, because the kinetics of NO release are dependent 
on so many variables the rate order is often inconsistent. RSNOs’ response to environmental 
stimuli is important for the practicality of device storage as well as potentially offering a means 
to control NO release during medical applications.9–12  
During research for this chapter, the following properties are evaluated for the most 
promising RSNOs: 
 Storage stability (varying temperature and light exposure) 
 Effect of phase on NO release (neat, solution, polymer) 
 Duration and flux of NO release (polymer specific) 
 RSNO Leaching (polymer specific) 
 Activity toward reducing platelet adhesion 
These factors serve as ideal goals for designing novel RSNOs and developing a NO 
releasing biomaterial with improved biocompatibility.1,3,13  The model RSNO incorporated 
polymer system is depicted in Figure 2.1.  After determining the lipophilic RSNOs with superior 
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performance based on the above criteria, and optimizing behavior in the most promising 
polymers, they were tested for their ability to decrease platelet adhesion.  NO has previously and 
consistently demonstrated the ability to reduce platelet adhesion and consequently inhibit 
thrombus formation.14  Demonstrating that the target RSNO/polymer systems can do this 
suggests they possess the potential for improving the biocompatibility of the biomaterial with 
regard to thrombus formation.  
2.2 Experimental 
2.2.1 Materials  
N-Acetyl-DL-penicillamine (NAP), penicillamine, acetic anhydride, pyridine, glutathione, sodium 
chloride, magnesium sulfate, sodium phosphate dibasic, potassium phosphate monobasic, 
ethylenediaminetetraacetic acid (EDTA), tetrahydrofuran (THF), sulfuric acid, diethyl ether (Et2O), N,N-
dimethylacetamide (DMAc), hexane, chloroform (CHCl3), silica gel, molecular sieves, methanol (MeOH), 
sodium nitrite (NaNO2), t-butylnitrite (t-BuNO2), n-butylnitrite (BuNO2), methylnitrite, ethylnitrite, 2-
butylnitrite (sec-BuNO2), dodecanethiol (DDT), 6-undecanone (UDT), tert-dodecylmercaptan (TDM), tert-
butanethiol (TBT), n-butyl lithium (n-BuLi), d6-chloroform (CDCl3), dimethylsulfoxide (DMSO), 
Figure 2.1. The model NO-release system utilizes polymers incorporated with RSNOs. As NO is 
released it has the ability to prevent platelet activation, and thus inhibit thrombus formation.  This 
contrasts with the control polymer, where clot formation can occur following the unimpeded platelet 
adhesion.  
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triphenylmethanethiol (TPMT), 1S-hexanethiol, 1S-octanethiol, 1S-decanethiol, 1S-hexadecanethiol 
(HDT), 1S-octadecanethiol (ODT), cholesterolthiol (ChoT), hexylamine  were purchased from Sigma-
Aldrich (St. Louis, MO).  Hydrochloric acid and sulfuric acid were purchased from Fisher Scientific 
(Pittsburgh, PA).  Tecophilic SP-60D- 60 and Tecoflex SG-80A were obtained from Lubrizol Advanced 
Materials Inc. (Cleveland, OH).  Dow Corning RTV 3140 Silicone Rubber (SR) was purchased from Ellsworth 
Adhesives (Germantown, WI).  CarboSil 20 90A was obtained from the Polymer Technology Group 
(Berkeley, CA).  Elast-eon TM E2As was purchased from AorTech International, plc (Scoresby, Victoria, 
Australia).  Fresh platelet rich plasma from a pig was obtained from Dr. Robert H. Bartlett’s laboratory in 
the Department of Surgery, University of Michigan Medical School.  All aqueous solutions were prepared 
with 18.2 MΩ deionized water using a Milli-Q filter (Millipore Corp., Billerica, MA). Phosphate buffered 
saline (PBS), pH 7.4, containing 138 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, 100 µM EDTA was 
used for all in vitro experiments. 
2.2.2 2,2-Dipentyl-[1,3]dithiolane Synthesis 
                                         (rxn 2.1) 
 The thioketal was prepared using a previously reported method.15  Briefly, 6-undecanone, 
1,2-ethanedithiol, TsOH, and benzene were added to a round bottom flask and azeotropically 
distilled.  The reaction mixture was washed with water, and the organic layer dried with MgSO4 
before removing the benzene via rotary evaporation.   
2.2.3 6-Undecanethiol Synthesis  
                             (rxn 2.2) 
 This thiol was synthesized as reported previously.15  Briefly, 2,2-dipentyl-[1,3]dithiolane 
was added to 0 ◦C Et2O under N2.  Excess n-BuLi was added dropwise via a syringe and allowed to 
warm to RT overnight.  After quenching the solution with water, the organics were separated, 
dried with MgSO4, and the Et2O removed via a stream of N2 to give a red/brown liquid.  
2.2.4 N-(2,2-Dimethyl-4-oxothietan-3-yl) acetamide Synthesis 
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The thiolactone was prepared using an established method.16  Briefly, penicillamine was 
dissolved in pyridine and chilled to 0 oC.  Two and two tenths (2.2) equiv. of acetic anhydride 
were added dropwise and the solution warmed to room temperature for ~20 h.  Dilute HCl was 
added and the thiolactone extracted into CHCl3.  The orange residue was dissolved in EtOH and 
precipitated from -78 C pentane. 
2.2.5 2-Acetamido-N-hexyl-3-mercapto-3-methylbutanamide (SNHC6H13) 
 
 The NAP amide derivative was synthesized using a variation of a previously reported 
method.16  The thiolactone above was reacted in chloroform with hexylamine for 24 h, washed 
with dilute HCl, and dried with MgSO4. 
2.2.4 General Nitrosation 
                                     RSH  +  RNO2  RSNO + ROH                          (rxn 2.5) 
Nitrosations of a wide variety of thiols are well documented and straightforward.17 
Lipophilic thiols are typically nitrosated in THF or Et2O using t-BuNO2 at room temperature 
(RT).17,18  All nitrosations were performed in vessels wrapped in aluminum foil so as to exclude 
light.  Nitrosations are not particularly sensitive to equivalents used, most often only requiring a 
slight excess of nitrosating agents (1.1-2.0 eq.).18  The majority of nitrosation reactions for the 
RSNOs prepared herein were completed in less than 45 min, commonly with quantitative yields.  
Purifications typically required only rotary evaporation so as to remove excess nitrosating agent 
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and the t-BuOH byproduct.  The percentage of RSNO obtained following synthesis can readily be 
determined by stimulating NO release with heat/light/Cu(I) while the sample is attached to a 
chemiluminesence nitric oxide analyzer (NOA).  The direct 1:1 ratio between NO/RSNO allows 
NO integration to correlate with the amount of RSNO tested.  For tests to determine the extent 
of nitrosation, product solutions were exposed to heat/light to convert all RSNO to disulfide 
(RSSR).19  Variations on specific RSNOs’ nitrosation procedures are mentioned in their respective 
sections, below. 
 
2.2.5 Preparation of RSNO-Doped Films 
 A known mass of RSNO was dissolved in a THF/polymer solution.  The solution was stirred 
for a few minutes to ensure homogeneity of the film casting solution composition.   The solutions 
were then cast into Teflon rings on a Teflon plate and dried overnight under a low stream of N2.  
Following solvent evaporation, discs were punched out of the films using a d=0.7 cm hole punch, 
weighed, and if desired for the experiment, dip-coated in a pure 200 mg polymer/4 mL THF 
solution before being dried under vacuum.7    
 
2.2.6 NO Release Measurements 
Nitric oxide was measured using a Sievers chemiluminescence Nitric Oxide Analyzer 
(NOA) 280 (Boulder, CO).  Samples were placed in the sample vessel either neat, dissolved in 
DMSO, or when in films, immersed in PBS (pH 7.4) containing 100 µM EDTA.  Nitrogen was 
bubbled into the solution.  Nitric oxide was then purged and swept from the headspace using the 
N2 gas stream into the chemiluminescence detection chamber of the NOA.  The sample vessels 
varied depending on the experiment—either clear or amber cells were used to provide control 
over light exposure.  The RSNOs or RSNOs within polymer films were exposed to a light source 
(100 W halogen floodlight (GE model 17986)) at variable distances for photolysis experiments, as 
well as heated in a water bath.  If applicable, a DMSO/CuSO4/cysteine solution could be injected 
to catalyze NO release.  To ensure film samples remain submerged in the chamber buffer during 
experiments, they were impaled on needles and suspended in solution to measure NO release 
rates with the NOA.19   
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2.2.7 Determining the RSNO Levels in Polymer Films 
For initial experiments, the amount of RSNO was determined by stimulating NO release 
from a piece of polymer with a known mass using heat, light, and a Cu(II)/cysteine solution, and 
integrating the NO release curve.  After obtaining the molar absorptivity of compounds, the 
amount of RSNO in a polymer could also be determined by extracting the RSNO content into 
solution (usually CHCl3), or as with the case of soluble polymers, dissolving a known mass (usually 
in THF or DMAc).19  
 
2.2.8 Determining the RSNOs’ Molar Absorptivity Coefficients 
 Given the fact that an unknown amount of RSNO could have decomposed during sample 
preparation, it was necessary to determine the percent of RSNO which was attributable to the 
mass being tested.  Consequently, solutions of the various RSNOs were simultaneously injected 
into the NOA sample cell and also tested on the UV-Vis Spectrophotometer.  The ratio of 
RSNO:mass could then be used to back calculate the amount tested on the UV-Vis 
spectrophotometer, so as to obtain an accurate molar absorptivity of the given RSNO at the max 
around 340 nm.19  
2.2.9 Storage Stability Studies 
The new RSNOs were tested for stability in neat as well as in solution and polymeric 
phases under various conditions including -20 ◦C freezer, 4 ◦C refrigerator, RT cupboard, north or 
west facing windowsills, shelves exposed to ambient room conditions and some sun exposure, 
or a dark PT oven.  Concentrations of RSNOs in the stored samples were tested at various time 
points as described above.  Samples were stored in vials for the duration of storage stability 
studies, with the films impaled on needles above desiccant.19 
2.2.10 Long Term NO-Release Measurements 
Stored films/needles were removed from vials and rinsed to physically remove any 
residual surface RSNOs, before testing their NO release as described above—taking care to 
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ensure measurement conditions were comparable to those during incubation (pH=7.4 PBS/EDTA, 
37 ◦C, dark).  The soaking buffer solutions were kept to test for leached species, if appropriate.7  
2.2.11 Leaching Measurements 
 The soaking solutions from the suspended films were shaken with immiscible solvent to 
extract/wash any leached species.  The solution was injected into the NOA or tested via the 
RSNO’s ultraviolet absorbance at ~340 nm to quantify the amount of leached (and non-
decomposed) RSNO.19   
2.2.12 Preparation of NO Releasing Polymer Coated Plates 
 Polymer/THF solutions were prepared with varying amounts of RSNOs dissolved in 
different samples.  After the solutions were homogenized, 0.25 mL aliquots were pipetted into 
the wells of a polypropylene 96-well plate.  The plates were dried for ~18 h under dark ambient 
conditions and ~6 h under vacuum.14  
2.2.13 In Vitro Platelet Adhesion Studies      
 Porcine blood was drawn into a citrate anticoagulant in a 9:1 volumetric ratio.  The blood 
with anticoagulant was centrifuged at 110 g for 15 min at RT.  The resulting platelet-rich plasma 
was collected and the [Ca2+] raised to 2 mM using CaCl2.  The polymers within the microtiter plate 
wells were prehydrated with 200 µL PBS at 37 C for 1 h.  After decanting the PBS, 100 µL of the 
recalcified platelet-rich plasma was added to each polymer-coated well.  The trays were 
incubated for 1 h at 37 C.  The PBS was decanted, and the wells washed with 200 uL of PBS.14     
2.2.14 LDH Assay 
 The lysing buffer was added to each well and incubated for 1 h at 37 C.  The tray was 
gently agitated.  One hundred µL of each lysate solution was then pipetted into a different 96-
well microtiter plate containing 100 µL LDH assay reagent.  After 1 h, each well’s absorbance at 
was monitored for 1 h.14 
2.3 Results and Discussion 
2.3.1 Nitrosations  
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RSNOs are nitrosated from the corresponding thiol via the chemical Reaction 1.3.  
Nonpolar thiols, particularly those insoluble in aqueous solutions, are commonly nitrosated using 
tert-butyl nitrite (t-BuNO2), as is the case in this work.  Acidified inorganic nitrite is the 
predominate nitrosating agent for thiols in aqueous solutions, such as SNAP.  The reactions are 
usually quantitative with potential impurities solely limited to unreacted thiol and the disulfide 
decomposition product.17,20  Given that RSNOs have intense colors (green for tertiary, red for 
secondary or primary alkyl substitution), their nitrosation and NO release can be observed 
visually for the most reactive species.  For example, the least stable RSNOs such as SNCT and 
SNODT exhibit a rapid loss of color within a matter of minutes.  Relating an RSNOs’ color change 
and NO release was developed into an undergraduate laboratory experiment (see Appendix A). 
 Depending on the stability of a given RSNO, some may have decomposed by the time the 
product is isolated.  If the decomposition is significant, the RSNOs are less useful for potential 
applications as a greater mass of the RSNO preparation would be needed to obtain comparable 
starting concentrations of RSNOs in the polymers.  The resulting higher concentrations of RSNO 
will increase leaching.  Such rapid decomposition also suggests they are unstable and storage 
would not be feasible for devices made with these RSNOs.  The main RSNOs that were prepared 
for this chapter are listed in Table 1 above, with the amount of RSNO present following 
nitrosation and separation indicated as well.   
Several variables were examined to rule out the less useful RSNOs and determine optimal 
conditions including nitrosating agent, solvent, temperature, and the reaction time.  Optimal 
conditions should minimize decomposition during nitrosations.  The most promising RSNOs, 
SNTDM and SNTPMT, as subsequent experiments will indicate, were obtained in pure form, 
following removal of solvent, excess nitrosating agent, and its byproduct (t-BuOH).  Their 
structures are shown below in Figure 2.2 with other RSNOs that are the most pertinent to this 
chapter’s experiments.  
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For the tested species, varying solvents had minimal effect on the RSNOs’ decomposition 
during nitrosation.  SNTDM, SNDDT, and SNHT were synthesized under comparable conditions in 
various solvents and their maximum concentrations noted in Table 2.2.  The highest 
concentrations (measured by UV absorbance) indicate the maximum level of RSNO and account 
for any loss by decomposition as well as incomplete nitrosation.  RSNO concentrations in hexane 
were slightly lower during synthesis than in the other solvents; however, these differences were 
minimal and would need to be repeated with additional samples and more frequent 
measurements to draw any clear-cut conclusion regarding the slight variation between levels.  
Figure 2.2. Structures of six RSNOs prepared in this work.  SNTDM and SNTPMT are the most 
promising lipophilic hydrocarbon RSNOs to date.  The primary RSNOs, SNDDT and SNHT, are 
less stable; however, they, along with SNTBT provide a useful contrast to explore the effects 
of the RSNOs’ structure on their behavior in response to various reaction and storage 
conditions.  SNAP is a stable and well-studied RSNO that serves as a point of comparison for 
several different testing methods employed in these studies.  
32 
 
Regardless, most follow-up nitrosations were not performed in hexane.  Although hexane is the 
least polar solvent, a trend regarding polarity was not observed given the fact DMSO is the most 
polar solvent yet it does not yield the highest levels of any of the RSNOs that were prepared and 
tested.  Other published RSNOs with lower aqueous solubility such as SNTDM have previously 
been synthesized using toluene, with further purification not performed nor explained.18,21,22  
Before subsequent experiments were conducted, the research groups accounted for the 
impurities but did not remove them.21,22  Given the negligible effects of solvent on NO release 
during preparation, those with low boiling point (BP) such as CHCl3, THF, and Et2O are most 
suitable for the research herein given their facile removal (see Table 2.2).  The effects of 
temperature were investigated as well.   
Increasing the temperature unfortunately did not prove to be advantageous.  Although 
elevated temperature may increase the reaction rate of nitrosation, it also increases the rate of 
thermal decomposition.  Decreasing the solvent’s temperature was somewhat beneficial for the 
less stable RSNOs.  The two effects are demonstrated by the synthesis of S-nitrosohexanethiol 
(SNHT), one of the least stable RSNOs.  SNHT was nitrosated at 0 ◦C, RT, and PT (see Figure 2.3). 
 
  
  
SNTDM SNDDT SNHT 
Hexane 93 92 93 
THF 95 102 97 
Et2O 94 95 97 
CHCl3 102 95 97 
DMSO 94 101 94 
 
Table 2.2. Shows the highest % of RSNO observed during a nitrosation in the listed solvents.  
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This suggests, at least for the less stable RSNO species (e.g., SNHT, SNCT, SNODT), that 
reducing the temperature decreases the rate of decomposition more than the rate of nitrosation 
and is thus advantageous.  Measurements were taken directly using aliquots without purification 
to minimize further NO release.  Although nitrosating hexanethiol at 0 ◦C allows 97.5 +/- 1.2 % 
RSNO to be present in the final product, biomedical applications would obviously require 
purification steps, which in the case of SNHT correlated with an additional loss of 15 % RSNO, 
making it not ideal for any potential real-world biomedical application. 
SNTDM was prepared in the literature at 0 ◦C;21  however, this was found not to be 
necessary and comparable yields were obtained in this work at RT.  This is likely because SNTDM’s 
stability is not significantly affected by being in solution phase rather than neat (longer durations 
are not detrimental).  This contrasts with SNAP, the common synthetic and very stable RSNO, 
that is commonly nitrosated at a decreased temperature, due to its diminished stability when 
dissolved in an aqueous solution.7  To test the effects of the nitrosating agent’s steric hindrance 
on degree of RSNO formation, different alkyl nitrites were used including n-butylnitrite, sec-
butylnitrite, iso-propylnitrite, and t-BuNO2 (see Figure 2.4 and Table 2.3).  Surprisingly, under the 
typical conditions, t-BuNO2 remained comparable if not the most successful nitrosation agent, 
despite its steric hindrance, even when nitrosating the bulky tertiary thiols SNTDM and SNTPMT.   
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Figure 2.3. SNHT’s nitrosation at different temperatures depicts the relative effects on the 
nitrosation and decomposition’s rate. n=3 
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  The UV-Vis experiments do not account for the concurrent decomposition that is 
occurring for these species; however, since three of the tested thiols are tertiary, and thus would 
be most sensitive to steric effects, the nitrosating agents’ structure also should also not play a 
role in the preparation of the less stable RSNOs.  SNDDT is stable enough that during the time 
period tested, no detectable NO is released (since purification was not performed).  
The more hindered RSNOs, SNTDM and SNTPMT, were nitrosated to a greater extent 
using increased reaction times, requiring approximately 30 and 45 min, respectively, with typical 
nitrosating agent levels (~1.1 equiv).  This is viable for SNTDM and SNTPMT since their heightened 
stabilities allow longer reaction periods.  The maximum RSNO concentration is obtained sooner 
for the other two species: 5-15 min for SNTBT and 5-10 min for SNDDT.  Using 1.1 equiv. t-BuNO2, 
the tertiary RSNO, SNTBT, is nitrosated after 10 min, which is longer than SNDDT, the primary 
RSNO.  Although all three are tertiary, SNTDM and SNTPMT likely take longer than SNTBT to reach 
a maximum RSNO concentration because the molecules themselves are considerably bulkier.  For 
all the tested species, it appears that the thiols’ substitution trumps the overall molecular bulk 
with respect to rate of reaction to form the RSNO.  This was indicated by the fact that SNDDT was 
fully synthesized in 10 min less time compared to SNTBT, despite being bulkier overall (see Figure 
2.5). 
Figure 2.4. Nitrosating agents of varying alkyl substitution. Nitrites are the most common 
class of nitrosating agent. 
Table 2.3. Time (min) until maximum UV absorption. 
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      While the majority of nitrosations are so rapid that a drastic color change is noted 
immediately, nitrosation to form SNCT and SNODT was found to be harder to observe due to a 
less intense color change.  This makes any qualitative indication of an approximate nitrosation 
time impossible (see Figure 2.6 for their structures).  Equimolar or a slight excess of nitrosating 
agents are predominately used in the literature, but very slow nitrosation was observed in the 
case of SNCT, and the reaction actually appeared to “stall” after 2 h, with only 73 % of the SNCT 
formed (compared to that expected).  This observed conversion was not lower due to 
decomposition, as after adding additional t-BuNO2 additional NO was produced.  SNHDT was not 
monitored by 1HNMR; however, a very slow color change was observed as well.   
 An increased amount of nitrosating agent was then used and the reaction monitored by 
1HNMR.  Whereas 1.2 equiv. of t-BuNO2 produced only 73% RSNO after 2 h, using 20 equiv. 
resulted in a complete nitrosation in under 5 min (see Figure 2.7).  The increased levels of t-
BuNO2 are viable for the reactions studied herein given the fact excess t-BuNO2 can be readily 
removed by rotary evaporation.  SNCT and SNODT’s behavior following nitrosation are discussed 
in sections 2.3.7 and 2.3.8, below.   
Figure 2.5. Nitrosation progress as indicated by the RSNO concentration in reaction mixture.  
Nitrosations used 1.1 equiv. of t-BuNO2. 
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 In summary, it has been found that a range of reaction conditions are similarly effective 
regardless of the thiol being nitrosated to produce a variety of lipophilic RSNO species.  Solvent 
plays a minimal role in nitrosating efficiency and consequently the more volatile ones are ideal 
Figure 2.7. The increased equivalents of t-BuNO2 greatly enhances the reaction rate of 
nitrosation of SNCT and the overall yield of the reaction.  
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Figure 2.6. Additional lipophilic RSNOs.  SNHDT, SNODT, and SNCT required longer nitrosation 
periods using the typical 1.1 equiv t-BuNO2 and also displayed less intense colors.  SNBzT was 
rapidly nitrosated and appeared stable; however, further research was not pursued given its 
noxious odor. 
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due to their facile removal.  t-BuNO2 proved to be an optimal or comparable nitrosating agent 
for both the starting primary and tertiary alkyl thiols that were converted to RSNOs.  Reduced 
temperatures were found to help preserve RSNO levels during nitrosation, however, this factor 
is only beneficial when working with the less stable (and less useful) RSNO species.  Reaction 
times were determined to be dependent on the specific thiol with the tertiary and bulkier thiols 
requiring longer reaction periods.  Increasing the rate of nitrosation, and thus reducing 
decomposition for the less stable species, is best achieved via use of excess nitrosating agent.  
The following species returned >90% RSNO following their synthesis and purification, making 
them the most viable candidates for potential biomedical applications: SNTDM, SNTPMT, SNTBT, 
SNDDT, SNUDT, and SNDT.  
 
2.3.2 Qualitative Stability Studies: RSNO Identity 
 Initial stability studies can indicate the feasibility of further application-based 
experiments as well as draw conclusions regarding how different structures of the various alkyl 
RSNOs’ influence stability.  For some of the RSNOs, stability can simply be monitored qualitatively 
via the characteristic color change corresponding to NO release (red/greenwhite).  While the 
stability of any RSNO is dependent on exposure to light/heat, if any of the RSNOs prepared in this 
work are drastically unstable under ambient light/temperature, the effects of additional 
conditions were not investigated in further detail.   
Qualitative decomposition studies indicated that the following RSNOs (see Figure 2.8) 
would have minimal value for further application testing (storage stability, leaching, long-term 
NO release, and anti-platelet studies).   
      
2.3.3 Preliminary Stability Studies: Alkyl Substitution 
Any correlation between substitution at the site of the nitroso functionality and the 
relative RSNOs’ stability, as indicated by the % recovery and preliminary studies, was not clearly 
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differentiated between species of varying structure and atomic content.  For example, although 
SNHT and SNDDT are both primary RSNOs, SNHT has released 8 % more NO after purification 
under ambient conditions.  Due to the fact that SNDDT, SNUDT, and SNTDM have comparable 
atomic content (11 or 12 saturated carbons), molecular masses, and phase at RT, their primary, 
secondary, and tertiary nitroso groups, respectively, are well-suited for comparing the effects of 
alkyl substitution on the lipophilic RSNOs’ stability (see Figure 2.9).18  This is also useful given the 
fact they lack additional heteroatom-functional groups.  Initially, it was hypothesized the 3 
different RSNOs could provide 3 unique NO-release profiles, allowing NO release specifically 
tailored devices useful for various applications such as RSNOs that release a quick burst of NO for 
facial acne ointments, or delayed NO release for biodegradeable, antibacterial stents.    
Solutions of the three RSNOs were evaluated for the relative effects of light exposure.  
When all three were exposed to direct sunlight, NO release increased accordingly, as expected 
from a continuum hν source.  Unexpectedly, a discrepancy was noted between the supposed 
stabilizing effects due to the alkyl substitution:  The stabilizing effect was evident between SNUDT 
and SNDDT, with the secondary RSNO having released 9% less NO after 6 hours of light exposure.   
Figure 2.8. RSNOs with considerable instability as indicated by rapid decomposition (color loss) under 
ambient conditions 
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Whereas 66 and 57% of SNUDT and SNDDT remained, respectively, only 9% of the tertiary RSNO, 
SNTDM, was present in the solution after this time.  
 
SNDDT 
 
 
 
SNUDT 
 
 
 
SNTDM 
Figure 2.9. SNDDT (231 g/mol), SNUDT (217 g/mol), and SNTDM (231 g/mol) share similar molecular 
masses, and minimal functional group thus facilitating a direct comparison of the effects of their 
primary, secondary, and tertiary alkyl substitution.  
Figure 2.10. SNTDM, SNUDT, and SNDDT’s response to stimulation by heat/light, and heat as 
indicated by the remaining % of initial RSNO.  Thermal degradation was monitored at RT, and the 
photo-release was accomplished using a 100 W halogen bulb as the light source. 
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The same three RSNOs were tested under identical conditions but without light exposure.  
The species were markedly more stable, and after 24 h each sample had significantly more RSNO 
remaining than after 6 h of light exposure.  By far the most significant observation, however, is 
that SNTDM is considerably more stable than SNUDT and SNDDT.  So although the tertiary alkyl 
substitution decreased the rate of thermal decomposition, the stabilizing effects from that alkyl 
substitution were less significant than the other structural differences (methyl groups) in regard 
to photo-induced decomposition.  SNTDM’s fascinating propensity for photolytic NO release will 
be further explored in Chapter 4.  Although the average concentrations of SNTDM, SNUDT, and 
SNDDT exhibit the expected trend for thermal induced NO release after 24 h, within error, there 
is no statistical difference between SNUDT and SNDDT.  There is a 10% difference between 
SNTDM and SNUDT, however, only a 2% difference between SNUDT and SNDDT. 
Silicone rubber films containing 1 wt% SNTDM, SNUDT, and SNDDT were tested using an 
NOA to monitor their real-time NO release profiles (see Figure 2.11).  Relative NO release curves 
correlated with the stability from Figure 2.10’s UV-Vis measurements.  Lower wt% loaded films 
were used, compared to other experiments, to minimize any potential leaching that would 
Figure 2.11. NO release flux from SR incorporated with SNTDM, SNUDT, and SNDDT 
over 3 days.  The dotted line represents the lower physiological threshold for NO 
release from endothelial cells.  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 24 48
Fl
u
x 
(m
o
le
s 
x 
1
0
E-
1
0
(c
m
-2
 m
in
E-
1
)
Hours
Effects of Alkyl Substitution on Thermal NO Release
SNDDT
SNUDT
SNTDM
41 
 
misrepresent the amount of RSNO remaining and thus the NO flux.  After < 1 d, the SNDDT films 
exhausted their NO reservoirs.  SNTDM, SNUDT, and SNDDT demonstrated NO release within the 
physiological range of endothelial cells (0.5-4.5 x 10-10 mol cm-2 min-1) for 3, 2, and <1 d, 
respectively.23  A direct correlation between the RSNOs’ alkyl substitution and NO release lifetime 
is apparent. 
 
2.3.4 Preliminary Stability Studies: Phase Dependence  
 To determine if an RSNO’s stability is dependent upon its phase, SNHDT (MP~20 oC) was 
tested for NO release on a NOA at both ambient (~25 oC) and slightly reduced temperatures (~15 
oC). The impact of phase effects is inherently dependent on the molecules’ functional 
groups/mass/etc.  SNHDT works well for this experiment, because its melting point phase 
transition temperature lies very close to RT and it does not require significant input of heat to 
trigger melting—which would rapidly release NO from the other RSNOs with higher or lower 
melting points and increase the difficulty of drawing conclusions.   Reducing an RSNO’s storage 
temperature is also expected to slow its NO release, regardless of phase.  Consequently, it was 
important to observe the effects of temperature change independently of phase.  SNHDT’s NO 
release was observed at 1, 8, 15, 22, 30, and 37.5 ◦C.  RT and PT temperatures are exact; however, 
the intermediate temperatures are approximate and were created by adding warm water to cold 
while monitoring solution temperature with a thermometer.  Due to the molecule’s relative 
instability, constant release values are not easily obtainable; however, the release curves (Figure 
2.12) provide a valid comparison.  The trend between temperature and NO release is evident as 
shown in Figure 2.12, although the changes in NO release only have small variations between the 
range of temperatures examined.  The change in NO release observed between the solid at 15 ◦C 
and the liquid at 22 ◦C is not more substantial than the same-phase transitions.  One difference, 
although slight, is an increase in the “burst release” of NO in the solid to liquid phase change.  
This phenomenon is common among RSNOs19 and may have some dependence on the liquid vs 
solid phase of the species.  Intermolecular interactions are likely predominately Van der Waal’s 
forces, which are weak enough to not show significant effects on the NO release.  Molecules that 
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would partake in hydrogen bonding would almost certainly exhibit a greater phase stability 
effect.      
 
 
2.3.5 Preliminary Stability Studies: Molecular Mass 
 A distinct trend was observed between the % RSNO recovered following purification, and 
the stability following storage (3 h).  This trend, however, was determined to not be a direct 
correlation with the RSNOs’ mass since SNHT has the lowest mass, but not the least stability (see 
Figure 2.13).  
Figure 2.12. The relationship between temperature and NO release from both the solid 
and liquid phases of SNHDT. 
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2.3.6 S,S-Dinitrosolipoic Acid (SDNLA) Results 
Lipoic acid and its reduced form, dihydrolipoic acid, are physiological sulfur-containing 
compounds that are antioxidants (see Figure 2.14).24  Lipoic acid has been approved by the FDA 
and is sold as an over-the-counter antioxidant.  We synthesized S,S-dinitrosolipoic acid to 
evaluate its stability given the fact that the RSSR decomposition product is physiologically safe.  
The RSNO was successfully prepared as indicated by the downfield shifts of the protons on the 
carbons adjacent to the sulfurs, “2a” and “4a”, as well as the alpha protons relative to the 
carboxylic acid “6a” (see the 1HNMR in Figure 2.14).  The thiol’s protons are also absent following 
nitrosation as indicated by the disappearance of shifts “1a” and “5a”.  SNAP’s high stability is 
partially attributable to intramolecular stabilization involving the carboxy and/or acetamide 
functional groups.  Consequently, we tested SDNLA in the freezer, cupboard, and shelf to observe 
its stability.  After 1 d, NO release was not detected from the cupboard and shelf samples, 
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Figure 2.13 Testing for correlation between the RSNOs’ mass and stability. Results were 
indicated by the % remaining following storage for 3 h at RT in absence of light.  Parentheses 
indicate the amount of RSNO following purification (which was accounted for). 
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indicating complete decomposition.  Following 1 wk of freezer storage the NO release was barely 
detectable as well.  SNAP has practically zero decomposition during comparable periods of similar 
exposures.  
 Even though SDNLA contains a secondary nitroso group it rapidly releases NO.  The 
proximity of lipoic acid’s nitroso groups likely facilitates this RSNO’s instability, since the 
intramolecular disulfide formation results in a five-membered ring.  Additionally, as indicated by 
the appearance of many additional NMR peaks in Figure 2.14c, NO release also occurs from 
intermolecular disulfide formation.  These results were not particularly promising; however, the 
RSNO was incorporated into SR films to see if the lifetime could be extended from SR bonding or 
crystallization within the polymer phase.  Following the standard preparation conditions and 
times only 17% RSNO remained, thus indicating that, unfortunately, SDNLA is not a viable RSNO 
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Figure 2.14. The reduced form of lipoic acid (a) forms a di-nitroso compound (b) before 
subsequently decomposing to oxidized lipoic acid (c) with additional side products—likely the 
result of intermolecular disulfide formation.  
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for biomedical devices.  In the future, synthesizing lipoic acid analogs with the thiols at varying 
distances from one another may serve as a means to provide species with varying NO release 
profiles; i.e. nitroso groups at carbons 5 and 10 could provide a more stable RSNO since the NO 
release would result in a less favorable 7-membered ring.  
 
2.3.7 S-Nitrosocholesterolthiol (SNCT) Results 
SNCT has not previously been reported in the literature.  It is an analog of an abundant 
lipophilic physiological molecule (cholesterol) and a secondary RSNO, thus we felt investigating 
its properties was valuable.  Nitrosation was performed using typical conditions; however, the 
reaction rate necessitated increased t-BuNO2 concentration.  Using 1.2 eq t-BuNO2 produced only 
30% product after 30 min while 20 eq t-BuNO2 resulted in complete conversion in less than 5 
min.  While the upfield and strictly aliphatic region is rather convoluted, pure SNCT was obtained 
and confirmed by the downfield shift of the proton adjacent to the thiol group, “1”. The alkene’s 
proton, “2”, can also be observed to shift (see Figure 2.15). 
NO release was not observed from a 5 mM SNCT/CDCl3 solution after 1 h at RT without 
light as indicated by 1HNMR.  After 3 h of storage at PT, almost 50% had decomposed.  Although 
unstable inherently, we discovered SNCT exhibits decreased stability in the solid phase.  
Removing the CHCl3, t-BuNO2, and t-BuOH via rotary evaporation (<10 min, RT, ambient light) 
yielded a pink solid.  Unfortunately, rapid decomposition was immediately noted by the 
pinkwhite color change (<5 min, RSSR) indicating that SNCT is considerably less stable in the 
solid form.  The NO measured during complete decomposition indicated only 3% RSNO remained.  
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2.3.8 S-Nitrosooctadecanethiol (SNODT) 
 SNODT’s nitrosation was observed via 1HNMR, and like SNCT, required excess t-BuNO2.  It 
too exhibited a substantially higher rate of NO release as a solid, thus making it not practical for 
practical biomedical applications.  Following purification, accounting for the NO release as 
1 
1b 
1c 1b 
2 
2b 
2b 2c 
Figure 2.15. 1HNMR spectra for the downfield region of thiocholesterol, SNCT, and a partial 
decomposition product (SNCT and RSSR).  The protons adjacent to the sulfur shift downfield upon 
nitrosation, and upfield following NO release.  
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measured via the NOA, indicated that only 8% of SNODT remained.  Although SNODT was not 
investigated further beyond this point, interestingly, a unique decomposition pathway may have 
occurred as suggested by the appearance of otherwise inexplicable NMR shifts (data not shown). 
2.3.9 S-Nitrosotriphenylmethanethiol (SNTPMT) Initial Observations 
SNTPMT, like SNODT and SNCT, is a heavier solid RSNO with their MWs being 305, 315, 
and 431 g/mol, respectively.  We were initially curious whether it too would show substantially 
less stability in the solid phase.  After isolating the green crystals, no visible loss of color was 
observed even after several days of exposure to sunlight, contrasting greatly with the other two 
RSNOs.  Its remarkable stability will be further discussed/examined in Chapter 4.   
2.3.10 S-(3-Acetamido-4-(hexylamino)-2-methyl-4-oxobutan-2-yl) nitrothioite (SNAP-NHC6H13) 
SNAP is one of the most promising RSNOs studied to date, largely due to its considerable 
stability with regard to thermal and photolytic NO release.  One downside is its propensity to 
leach from polymers given its LogP=0.08.7,19  In attempt to ameliorate the leaching while utilizing 
SNAP’s stability, we prepared a novel analog, SNAP-NHC6H13, via a 3-step synthesis (see Figure 
2.16) and characterized this species by 1HNMR (see Figure 2.17).  Downfield shifts of the doublet 
“a” from 4.4 to 4.6 ppm, or the amide protons confirmed the presence of the nitrosation product.  
             
 
Figure 2.16.  SNAP-NHC6H13, a lipophilic SNAP derivative was prepared to potentially decrease its 
leaching.  Downfield shifts of the doublet “a” from 4.4 to 4.6 ppm can be seen in Figure 
2.17. 
a 
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2.3.11 Extended Environmental/Storage Stability Studies  
To be useful for biomedical applications, RSNOs must possess reasonable stability for 
practical storage conditions.  Within a medical setting, RSNO-containing medical devices could 
potentially be stored in a cupboard, refrigerator, or freezer.  Given a RSNO’s thermal and photo-
induced NO release, freezer storage is almost always most promising; however, it’s useful to 
understand the effects of various environments on devices’ NO-release and RSNO degradation.  
These experiments serve to provide a general comparison of the RSNOs’ stability with regard to 
variations in temperature, light exposure, and specific polymer.  Different polymers are known 
to provide unique stabilizing or destabilizing effects.  For example, Brisbois et. al. demonstrated 
that 10 wt% SNAP in E2As polymer (a co-polymer of polyurethane with poly(dimethylsiloxane) 
Figure 2.17. 1HNMR of the thiol precursor, NAP-NHC6H13, and the novel RSNO, SNAP-NHC6H13, 
following synthesis.  Downfield shifts of the doublet “a” from 4.4 to 4.6 ppm indicate the 
presence of the nitrosated product. 
a 
a 
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and poly(hexamethylene oxide) could provide a physiological flux of NO for 1 and 2 d longer than 
10 wt% SNAP in SR and CS, respectively, when exposed to PT and a 100 W floodlight.7    
The preparation time for RSNO containing polymers can potentially be detrimental to the 
total NO loading.  Preparation often requires drying overnight or even longer depending on the 
polymers’ thickness and number of topcoats.  Casting films containing 5 wt% RSNO resulted in 
minimal loss for the most stable species, SNTDM and SNTPM, with 10% or less lost for each of 
the polymers tested.  In contrast SNTBT lost 32% in SR and 24% in E2As and CS.  Following 
preparation, 62% of SNDDT’s NO had been released in SR and 66% in E2As and CS.  SNTBT and 
SNDDT’s concentrations were increased for the casting process as indicated in Table 2.4.  This 
resulted in all of the polymer/RSNOs’ films to be more equal in their RSNO loading following 
preparation.  Although starting RSNO levels were similar, the SNTBT and SNDDT films contained 
significantly higher levels of their RSSR decomposition products which likely resulted from 
increased leaching into aqueous solutions in contact with the film surface.  Following 
preparation, films were used for various experiments.  Some films were immediately carried onto 
stability testing, while others were prepared for NO-release or leaching studies.  
 
SR films with 5 wt% SNTDM, SNTPMT, SNTBT, and SNDDT were stored in a -20 °C freezer, 
RT cupboard, and a RT shelf approximately 3 m from a westward facing window (see Figure 2.18).  
All RSNOs showed the slowest NO release under freezer storage conditions, as expected.  
Increasing to RT with no light (cupboard) decreased their stability.   
 SR  CS E2As 
SNTDM 4.7 4.5 4.5 
SNTPMT 4.6 4.7 4.6 
SNTBT 3.4 3.8 3.8 
SNDDT 1.9 1.7 1.7 
 
 
 RSNO/polymer (mg) SR  CS E2As 
SNTDM 10:190 4.7 4.5 4.5 
SNTPMT 10:190 4.6 4.7 4.6 
SNTBT 13:187 4.4 4.6 4.7 
SNDDT 13:187 4.8 4.9 4.6 
Table 2.4. Determining RSNO/polymer ratios to improve consistency in wt% loading.   
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Figure 2.18. SR films prepared with 5 wt% SNTDM, SNTPMT, SNTBT, and SNDDT 
stored in a (a) freezer, (b) cupboard, and on a (c) shelf.  n=3 
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    In both environments SNTDM and SNTPMT were substantially more stable than SNTBT 
and SNDDT, and comparable to one another within error.  During shelf storage, as observed 
during the preliminary studies, SNTDM’s NO release greatly increased, and after six days 89% of 
the RSNO had decomposed.  During the same duration even SNDDT, the primary RSNO, had loss 
less NO (< 76%) (see Figure 2.18). 
5% SNTDM and SNTPMT were doped into SR, CS, and E2As to determine whether the 
polymers offered any stabilizing effects (see Figures 2.19 and 2.20).   Both of the RSNOs exhibit 
high stability in all three polymers as indicated by more than 90% of their NO intact after 4 weeks 
of freezer storage.  SNAP doped films were stored as well to provide a comparison.  Interestingly, 
SNTDM demonstrated the greatest stability in SR and the lowest in CS.  The opposite 
trend/correlation held true for SNTPMT. 
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Figure 2.19. 5 wt% SNTDM and SNAP incorporated into SR, CS, and E2As and stored at -20 C for 1 
month. n=3 
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 SNAP demonstrated better stability than STDTM in both E2As and CS; it contained 8 and 
13% more RSNO, respectively.  In SR, SNTDM, SNTPMT, and SNAP retained comparable amounts 
of NO intact after 4 weeks.  Although comparable during the initial three weeks, 2% more SNAP 
remained than SNTPMT in E2As films after the fourth week.   
As heat and light are known to be two major stimuli for RSNOs’ NO release, we expected 
their storage stability to be greatest in a -20 oC freezer, followed by 4 oC refrigerator, RT cupboard, 
ambient/shelf, and least in a sunny windowsill, respectively.  Indeed, the individual samples 
followed the expected trend; however, the stability between the three species did not follow an 
anticipated linear trend as hypothesized because their major structural variation was solely 
substitution at the site of the nitroso- functionality.  Instead we noticed that the tertiary RSNO, 
SNTDM, is significantly more stable under many conditions, whereas the primary and secondary 
species were quite comparable.    
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Figure 2.20. 5 wt% SNTPMT and SNAP incorporated into SR, CS, and E2As and stored at -20 C for 1 
month. n=3 
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SNAP-NHC6H13 was very unstable in all conditions tested.  In fact, even when stored in the 
freezer (-20 °C, dark), all three doped polymers prepared with this species had nearly 
decomposed within one month (data not shown).  SNAP, on the other hand, maintains nearly 
quantitative levels during the same duration.  The fact that SNAP-NHC6H13 is an oil in its pure, 
isolated form. as opposed to SNAP which is a crystal, is hypothesized to account for this 
phenomenon.   
 
2.3.12 Leaching Studies 
Five wt% films doped with SNTDM, SNTBT, SNTPMT, and SNDDT were evaluated for their 
leaching from three polymer phases: SR, E2As, and CS which were stored in a soaking solution of 
PBS/EDTA at 37.5 °C.  As repeatedly reported in the literature, doped molecules commonly leach 
most significantly during the initial time periods following submersion/exposure to aqueous 
buffer solutions.5,7,19  This is likely caused by water uptake into the polymer which then displaces 
the RSNO compound.  Fortunately, this is not problematic with the studied systems given the 
RSNOs’ decreased aqueous solubility. For example, assuming the logP gives a reasonable 
representation of the RSNOs partition between the lipophilic polymer and surrounding aqueous 
solution, it would require a 1,000,000:1 water:octanol volume ratio to displace 50% of the 
SNTPMT from a polymer (LogP=6.0).  Given SNAP’s logP=0.08, it would only require 
approximately a 1:1 volume ratio to displace 50%.   
Since the most significant leaching occurs soon after submersion (and thus before 
significant decomposition) the measured RSNO species represents the majority of the leached 
content.  This is sufficient for shorter-term devices; however, for more stable RSNOs, and 
biomedical devices potentially used for longer applications, accounting for leached RSSR will give 
a more accurate depiction of the total leached species.  The RSSR concentration will also be 
monitored in Chapters 3 and 4.  
The % of leached RSNO for SNTDM, SNTPMT, and SNDDT was substantially lower than 
SNAP in each polymer over the entire soaking duration (see Figure 2.21).  Between the most 
lipophilic compounds, SNTDM, SNTPMT, SNDDT, and the tested polymer systems, there was no  
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apparent trend between the logP values and total % leached.   
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Figure 2.21. The % of leached RSNO from (a) SR, (b) E2As, and (c) CS films doped with 5 
wt% SNTDM, SNTPMT, SNDDT, SNTBT, and SNAP. 
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Comparing the total leached values after 3 d of soaking at 37.5 °C, SNTDM, SNTPMT, and 
SNDDT had approximately 14%, 15%, and 12% less leached RSNO than SNAP from SR, E2As, and 
CS, respectively.  There was a clear difference between the least lipophilic compound, SNTBT, 
and more lipophilic compounds.  In fact, in E2As and CS, SNTBT leached nearly the same as SNAP 
during the tested duration: 15% and 13%, respectively. 
Whereas SNAP, SNTDM, and SNTPMT’s leaching values are accurate (due to their 
substantial stability), SNDDT and SNTBT’s leaching is likely greater than the RSNO values reported 
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Figure 2.22. SNDDT’s low stability likely causes the leached RSNO concentration to not 
accurately reflect the total leached content. 
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in the figures above.  This is demonstrated in Figure 2.22 with SNDDT.  After 1 day, 4% SNDDT 
had leached into the PBS while 50 % of the RSNO had already decomposed.  It is likely that some 
of the 50 % that had decomposed (now a disulfide) had also leached into the PBS soaking solution 
and is not detected by UV absorption.  Additionally, some RSNO may have leached and then 
decomposed, once again confounding the total leached content.   
 
2.3.13 Long-Term NO Release 
Biomedical devices require replacement so as to reduce the risks of a blood clot or 
infection associated with thrombosis or biofilm formation, respectively.  Extending the duration 
of a biomedical device’s use is advantageous since replacing it can introduce bacteria into the 
patient and increase the risk of infection.3,7  Prolonging a device’s use can also reduce costs and 
minimize a patient’s discomfort.19  Biomedical grade polymers that release NO have the potential 
for extended implantations since NO deters thrombosis and biofilm formation.7   
SNTDM, SNTPMT, and SNAP were incorporated into SR, E2As, and CS films, and their NO 
release monitored periodically during prolonged exposure to physiological conditions which 
emulate an intravascular or lower urinary-tract environment (dark, 37 C◦) (see Figure 2.23).  
SNAP’s NO release from each of the polymers has previously been published and agrees well with 
the results observed here.1,3,7,9  SNTDM and SNAP both released NO at or above the lower-
threshold physiological NO flux of endothelial cells (0.5 x 10-10 mol cm-2min-1) for 1 month.1  
Whereas SNTPMT/E2As films also released NO for approximately 1 month, SR and CS films 
containing 10 wt% SNTPMT exhibited superior lifetimes, lasting at least 41 d at or above 0.5 flux. 
This duration of NO release at or above 0.5 flux has not previously been observed from a polymer 
loaded with 10 wt% of any RSNO species. 
 
57 
 
 
 
Figure 2.23. NO release measurements from 10 wt% SNTDM, SNTPMT, and SNAP in 
SR, E2As, and CS films stored at 37C in the dark over time. n=3 
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2.3.9 Platelet Adhesion Studies 
Thrombus formation on biomedical devices is attributable to serious health concerns such 
as blood clots/embolisms.  Additionally, a thrombus can impact device function, especially if that 
device is used for bio-analyte sensing or requires blood flow over its surface.  Platelet adhesion 
is one of the fundamental early steps of the thrombosis mechanism, and scientists have 
previously demonstrated NO’s ability to prevent it.14   Research in the Meyerhoff group 
demonstrated that a PVC polymer doped with low levels of DBHD (0.5-4 wt%), a diazeniumdiolate 
type NO donor, can reduce platelet adhesion by 79%.14  We hypothesized that the RSNO species 
demonstrating the best stability, NO-release, and minimal leaching from the studies reported in 
this chapter could potentially decrease platelet adhesion on biomedical grade polymers.   
A 96-well plate was coated with a homogeneous polymer/RSNO/THF solution.  Given their 
promising NO release properties, SNTDM and SNTPMT were used as the RSNOs in this study and 
both species were incorporated into CS, E2As, and SR films.  After drying, the wells were exposed 
to PRP solutions and platelets were allowed to potentially adhere to the polymer.  After removal 
of the PRP solution, adhered platelets were exposed to a surfactant solution to damage their 
cellular membrane, resulting in the release of lactate dehydrogenase (LDH).  The solution of LDH, 
an oxidoreductase enzyme, was exposed to NAD+ which was consequently reduced to NADH (see 
Figure 2.24).  NADH is readily detectable via its absorbance at 450 nm.  Because NO release 
reduces the presence of adhered platelets, the hypothesis was that RSNO/polymer wells would 
have less platelets, and thus less NADH present.14 
 Pure polymer controls when exposed to PRP/surfactant provided a representation of 
their inherent propensity to adhere with platelets.  40% more platelets adhered to silicone rubber 
than E2As, while 31% more adhered to SR than CS. Within error, CS and E2As have comparable 
levels of adhered platelets (see Figure 2.25).  
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Figure 2.25. Control polymers inherent platelet adherence represented as a relative 
comparison of absorbance. N=3 
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Figure 2.24. Adhered platelets when lysed with a surfactant release LDH that in turn reduces 
NAD+ to NADH, the molecule tested.   
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1, 5, and 10% of the RSNOs were doped into SR, and each showed a direct correlation 
between increased RSNO levels and antiplatelet effects, as predicted (see Figure 2.26).  For every 
wt% tested, SNTDM and SNTPMT prevented more platelet adhesion that SNAP.  SNTDM and 
SNTPMT performed comparably with 1 wt% loading as both had 86% less platelets than the SR 
controls.  With 10 wt% loading, SNTDM/SR had only 3% the platelets as were found attached to 
the controls—a very low number.  SNAP/SR had 16% the number of activated platelets as the SR 
controls.   
For the E2As polymer, only 5 and 10 wt% loadings were tested due to limited blood 
availability (see Figure 2.27).  Again, SNAP and SNTDM demonstrated direct correlations between 
increased RSNO load and reduced platelet adhesion.  They performed similarly under the tested 
conditions.  SNTPMT performed uniquely; however, and upon increasing from 5% to 10 wt% 
loading the number of adhered platelets more than doubled.  Despite this, the levels of activated 
platelets were still 48% below that of the E2As control polymers.  Again, SNTPMT/CS wells 
exhibited a reverse relationship between the RSNO levels and any platelet reduction (see Figure 
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Figure 2.26.  SNTDM, SNTPMT, and SNAP’s effect on platelet reduction at 1, 5, and 10 wt% in 
SR (n=3).  % of adhered platelets are relative to controls (see Fig. 2.24). 
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2.28).  This time, increasing from 5% to 10 wt% resulted in 90% more adhered platelets relative 
to the control, nearly doubling the levels.  SNAP’s adhered platelets also increased going from 5  
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Figure 2.28.  SNTDM, SNTPMT, and SNAP’s effect on platelet reduction at 1, 5, and 10 wt% in CS 
(n=3).  % of adhered platelets is relative to controls (see Fig. 2.25). 
Figure 2.27.  SNTDM, SNTPMT, and SNAP’s effect on platelet reduction at 1, 5, and 10 wt% in 
E2As (n=3).  % of adhered platelets are relative to controls (see Fig. 2.25). 
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to 10 wt%, increasing by 24%; however, levels still remained 61% lower than the control.  
SNTDM’s 5 and 10 wt% wells reduced platelet adherence on CS by 21 and 12% relative to the 
controls, respectively.  
While the experiments indicate the relative effects of each RSNO/polymer, it is important 
to keep in mind that the number of decreased platelets does not mean there are necessarily less 
platelets overall since each polymer has a different level of platelets attached to the control films 
(see Figure 2.25).  In future studies a coulter counter will be used to provide a quantitative 
analysis of the specific platelet counts.  SNTPMT’s unexpected behavior could be partially be 
attributed to its solubility.  Any precipitated solid could affect the polymers’ surface texture 
(increased roughness), an attribute known to correspond with increased platelet adhesion.  This 
explanation likely fits with the SNAP-doped CS films as well, particularly since Wo et al. previously 
demonstrated that SNAP crystals are present in such films when SNAP is present  at or above 5 
wt%.9  In the future, SEM images will determine if the polymer surface is in fact affected in the 
case of the presence of SNTPMT within the polymers.  
 
2.4 Conclusions 
In this chapter, the potential of many lipophilic alkyl and aryl RSNOs’ was evaluated for 
use in biomedical applications.  Preliminary studies indicated that nitrosations of most of the 
species examined are nearly quantitative under the tested conditions, regardless of the thiols’ 
substitution, molecular mass, nitrosating agent, and solvent.  Despite this it was impossible under 
the tested conditions to obtain some of the RSNOs following purification.  The secondary and 
tertiary RSNOs required longer nitrosation times under the typical ~1.1 equiv. t-BuNO2 
concentrations.  This proved to be detrimental to the less stable species and resulted in 
undesirable premature NO release.  Increasing the equivalents of nitrosating agent allowed 
quicker nitrosations and thus can be employed given the typical purification methods, which 
remove the excess nitrosating agents.  Despite the increased nitrosation rates, the least stable 
RSNOs are not suitable for biomedical applications given their instability during isolation.   
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Preliminary studies examined the effects of the RSNOs’ inherent chemical characteristics 
and their corresponding NO release behavior.  Increased alkyl substitution correlated with 
enhanced thermal stability, as has previously been demonstrated with RSNOs bearing similar 
structures.  A substantial anomaly was observed, however, with regards to the tested RSNOs’ 
photoactivation as SNTDM exhibited extreme sensitivity compared to the SNDDT primary thiol 
isomer and secondary thiol SNUDT species.  This photo-instability will require devices to be 
stored in more stringent conditions; however, it may prove promising in the development of 
devices and applications utilizing light-induced NO release (e.g., topical phototherapy for wound 
healing or acne treatment, etc.).   
SNHDT’s solid or liquid phase appeared to play a minimal role in the RSNO’s stability as 
no significant change was noted upon freezing the molecule, except a slight increase in the initial 
NO “burst release”.  This trend may also apply for other RSNOs with minimal heteroatoms; 
however, RSNOs bearing additional functionality could exhibit different stabilizing effects 
(hydrogen bonding, etc.) due to their phase.  Any trend between the RSNOs’ molecular masses 
and stabilities was not evident with the primary substituted RSNO species that were tested.  The 
larger RSNOs, SNCT and SNODT, demonstrated significant instability, however, and given their 
more unique structures it is unlikely that their greater mass solely accounts for this behavior.  
When doped into SR films, SNTPMT and SNTDM exhibited substantial stability during 
cupboard and freezer storage.  Indeed, both had 90% or above NO loading retained even after 4 
weeks of storage under these conditions.  85% of the SNTDM inside the SR films remained after 
1 month exposure to sunlight, thus exhibiting a very surprisingly high stability.  SNDDT and SNTBT 
were unstable under the wide range of storage conditions tested.  Both RSNO compounds 
released all of their NO well before the end of the 1 month storage period on the shelf (RT, 
ambient light and 3 m from window) as well as in the cupboard (RT, dark).  Even in the freezer (-
20 °C), only 40% and 11% of the SNTBT and SNDDT remained, respectively, in the SR films 
following 1 month of storage.  SNTBT and SNDDT’s instability does not make them good 
candidates for biomedical applications.   
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SNTDM and SNTPMT were doped into SR, CS, and E2As and compared to SNAP’s stability 
during 1 month of storage in a freezer.  SNAP was more stable than SNTDM in all polymers except 
SR, in which they both retained ~94% NO after 1 month.  Films made from E2As and CS contained 
10% and 12% more SNAP than the SNTDM counterparts, respectively.  SNTPMT demonstrated 
excellent stability and performed comparably to SNAP in all polymers with the exception of E2As, 
in which 95.7 ± 0.6% SNTPMT vs 98.4 ± 0.9 % SNAP remained. 
Leaching of the RSNO compounds from SR, E2As, and CS polymer membranes was 
quantitated and compared to SNAP’s leaching behavior.  SNTDM, SNTPMT, and SNDDT exhibited 
substantial retention within the hydrophobic polymer.  However, both SNAP and SNTBT 
demonstrated significant leaching into the surrounding aqueous buffer solutions, very likely 
resulting from their lower LogP values and thus increased aqueous solubility.  SNTBT’s leaching 
combined with its decreased stability makes it inferior to SNTDM and SNTPMT for potential 
biomedical applications. 
Finally, the effect of SNTDM and SNTPMT’s NO release as assessed via surface platelet 
adhesion was determined using PRP obtained from citrated porcine blood and compared to that 
demonstrated by SNAP.  SNTDM and SNTPMT performed very well when incorporated into SR 
polymer films and exhibited less platelet adherence than SNAP at each of the tested wt% levels.  
At 10 wt% loading, only 3.0 % platelets (relative to control levels) had adhered to the SNTDM/SR 
polymer.  SNTDM outperformed the other RSNOs in CS at 10 wt% and showed only 12% as many 
adhered platelets as the controls. 
The data for SNTDM, SNTPMT, and SNAP’s performances during this chapter’s most 
important experiments are summarized in Table 2.5 below.  As reported in the literature, many 
RSNOs often excel in one facet of their performance while they lack in other(s).18,21,22,25  Due to 
this, certain RSNOs are better suited for certain applications than others.  SNAP, more so than 
other RSNOs, has consistently proven superior given its relative high stability under both thermal 
and light exposure.9  This gives SNAP exceptional storage capacity and provides an extended NO 
release for biomedical applications, characteristics which have impeded RSNOs’ clinical progress.  
One of SNAPs downfalls, however, has been its leaching from biomedical grade polymers.  
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Although SNAP is stable, its propensity to leach from the polymer films containing it into aqueous 
solutions in contact with the surface limits its utility in regard to localized treatments.  The most 
promising new lipophilic RSNOs studied herein, SNTDM and SNTPMT, exhibited substantially 
lower leaching under all the tested conditions.  Preliminary studies show that SNTPMT is at least 
comparable to SNAP while in the crystalline phase with respect to resistance against 
decomposition in ambient light and temperature exposure, a characteristic not previously 
reported in the literature to the best of our knowledge for any RSNO.  Future work will further 
examine SNTPMT’s behavior in polymers regarding its longer-term stability to explore if its 
behavior is comparable to that observed in its crystalline phase.  Although SNTDM is less stable 
than SNTPMT and SNAP under the tested conditions, its increased NO release profile 
demonstrates greater efficacy towards preventing platelet adhesion. 
 
 
 
SNTDM SNTPMT SNAP 
Leaching-SR (5 wt%) 2.4 ± 0.4% 2.0 ± 0.2% 15.9 ± 2.8% 
Leaching-CS (5 wt%) 3.1 ± 0.5% 1.8 ± 0.3% 14.1 ± 2.5% 
Leaching-E2As (5 wt%) 2.3 ± 0.4% 1.5 ± 0.3% 17.2 ± 1.9% 
Freezer-SR-4 weeks (5 wt%) 93.1 ± 0.7% 92.0 ± 2. % 94.0 ± 1.1% 
Freezer-E2As-4 weeks (5 wt%) 90.2 ± 1.3% 95.7 ± 0.6% 98.4 ± 0.9% 
Freezer-CS-4 weeks (5 wt%) 88.0 ± 1.8% 99.0 ± 1.3% 101.0 ± 0.3% 
Relative Platelet Adherence (CS) 12.3 ± 2.0% (10) 22.1 ± 5.9% (1) 15.2 ± 0.1% (10) 
Relative Platelet Adherence (SR) 3.0 ± 0.3% (10) 8.6 ± 0.1% (10) 16.2 ± 0.1% (10) 
Relative Platelet Adherence (E2As) 14.0 ± 3.4% (10) 23.8 ± 6.2% (5) 12.0 ± 2.0% (10) 
Long-Term NO Release (CS) 28 d 41 d 28 d 
Long-Term NO Release (SR) 28 d 41 d 28 d 
Long-Term NO Release (E2As) 28 d 33 d 33 d 
Table 2.5. Comparison of SNTDM, SNTPMT, and SNAP’s best results for leaching, stability, long-term 
NO release, and antiplatelet experiments.  Superior results are indicated in bold.  Best wt% in the 
platelet studies are indicated in parentheses. 
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CHAPTER 3. 
THE PREPARATION AND CHARACTERIZATION OF NITRIC OXIDE RELEASING 
SILICONE RUBBER MATERIALS IMPREGNATED WITH S-NITROSO-TERT-DODECYL 
MERCAPTAN 
 
3.1 Introduction 
As indicated by the results presented in Chapter 2, S-nitroso-tert-dodecyl mercaptan 
(SNTDM) possesses traits that are promising for the RSNO’s future use in biomedical applications 
including long-term NO release, minimal leaching (from hydrophobic polymers), reasonable 
storage stability, and antiplatelet activity.  Continued investigation of this molecule within this 
chapter involved development of a solvent swelling technique to effectively impregnate the 
SNTDM into catheters.  The NO release behavior was determined in unique environments and 
the performance optimized for antimicrobial studies with S. aureus.  The effects of an EtO 
sterilization technique on RSNO concentration were also tested as well given that that the 
conditions can be detrimental to the RSNO inside.  This chapter was published in The Journal of 
Materials Chemistry B (2016, 4, 422-430).  
 Silicone rubber (SR) has become one of the most common polymers used to prepare 
biomedical devices since it was first introduced to the medical field in the 1940’s.  Its low 
compression set, robust mechanical properties, chemical and temperature resistance, as well as 
intrinsic flexibility for melding and extrusion processes have allowed its use for numerous health 
care applications including shunts, implants, medical adhesives, and catheters.  Silicone rubbers 
69 
 
have demonstrated greater biocompatibility and biodurability for certain applications compared 
to other common polymeric materials.  Polyurethanes lack stability over as broad a temperature 
range compared to polydimethylsiloxanes, which potentially limits sterilization techniques or 
storage conditions.  Exposure to organic solvents such as acetone and isopropyl alcohol, which 
are commonly found in adhesives and disinfectants, can solubilize polyurethanes and lead to 
surface cracking.  Unlike polyurethanes, silicone rubber catheters are resistant to hydrolysis due 
to their high crosslinking.  Silicone rubber’s lower compression set provides increased flexibility 
and resistance to deformation.  PVC commonly requires plasticizers, which are known to leach 
from the materials during use.  Silicone rubber's stability also lends itself to sterilization by 
ethylene oxide (EtO), a process often used to sterilize biomedical devices prior to medical 
procedures.1-5 
Despite these characteristics, introducing any foreign material such as an intravenous or 
urinary catheter within a patient can cause health complications including urinary tract or 
bloodstream bacterial infections.2  Although progress has been made in preventing catheter-
related bloodstream infections (CRBIs), such complications remain prevalent and are estimated 
to cost between 670 million and 2.68 billion dollars annually in the United States alone.6  Urinary 
tract infections (UTIs) are the most common, with catheter-associated infections accounting for 
approximately 75% of occurrences.7  Microbial biofilms commonly form on the surfaces of 
biomedical devices. Bacteria release extracellular polymeric substances that form a hydrated 
matrix.  Bacteria within a biofilm community undergo significant phenotypic changes while in the 
matrix.  Bacteria present within a biofilm demonstrate antibiotic resistance due to adaptive stress 
responses and poor antibiotic penetration, as well as protection from the host’s immune 
system.8-10  Staphylococcus aureus is the most common cause of nosocomial bloodstream 
infections, specifically those associated with biofilm formation on indwelling biomedical 
devices.11  It can cause a range of illnesses, from skin infections to life-threatening diseases like 
bacteremia or sepsis.  Given this and the ever-growing concern of antibiotic-resistant bacteria 
like methicillin-resistant Staphylococcus aureus (MRSA), developing effective ways to combat 
infections by this organism is crucial.6-11   
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Many methods have been studied to improve device biocompatibility such as surface 
modification, passive or bioactive coatings, and silver incorporation, each with their own 
advantages and disadvantages.12-15  Indeed, Ag+ eluting urinary catheters have not solved the 
problem given that The Healthcare Infection Control Practices Advisory Committee (HICPAC) 
states that silver-alloy coated catheters lead to similar infection rates compared to the 
conventional silicone ones.  Further, they have stated that routine irrigation of the bladder with 
conventional antimicrobials (antibiotics) is not recommended as it increases antimicrobial 
resistance.9,10  Recent work from our group has aimed to increase the biocompatibility and 
antimicrobial activity of medical grade polymers through the incorporation of nitric oxide 
releasing molecules.16-19  
Nitric oxide (NO) is an endogenous molecule that exhibits a diverse range of benefits 
including its antimicrobial, antithrombotic, and vasodilatory properties, all of which have use in 
improving the biocompatibility of medical devices. NO releasing polymers can provide treatment 
at localized sites, thus minimizing side effects and complications experienced with use of 
systemic or local antibiotics (e.g., drug interactions) and the ever growing concern of antibiotic 
resistant bacteria.17-19  Due to its propensity to readily oxidize, NO should be released from 
biomedical devices in controlled amounts, for specific durations, and at discrete locations. Regev-
Shoshani et al. successfully demonstrated that Foley catheters impregnated with NO gas could 
prevent E. coli colonization and biofilm formation; however, they acknowledge the model does 
not immediately translate to clinical environments in which catheters are exposed to high urine 
flow.20  Catheters exposed to dynamic urine flow for 24 h showed diminished bactericidal effects 
in the surrounding solution.20 Although antimicrobial activity was demonstrated for 24 h 
following 1 week of storage,20 retaining NO within polymers would be difficult for extended 
periods of storage without pressurized containers.  Given NO’s reactivity and the difficulties 
associated with the controlled delivery of this gas, various classes of NO donor molecules have 
been studied for potential use as an NO reservoir within polymers including diazeniumdiolates, 
S-nitrosothiols (RSNOs), metal nitrosyl compounds, and other nitrogen oxides.  
Some RSNOs are physiological NO donors, with endogenous species including S-
nitrosocysteine (CysNO), S-nitrosoglutathione (GSNO) and S-nitrosoalbumin present within the 
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human blood stream. Given these donors’ inherent biocompatibility, they have been thoroughly 
studied as a means to create controllable NO delivery from materials; however, each has 
limitations including low stability towards thermal and photolytic decomposition. These traits 
make device preparation and storage difficult.  Further, high water solubility enhances extraction 
out of the polymeric materials when in contact with blood or urine.  Nonetheless, various 
exogenous NO donors have been incorporated into biomedical polymers in attempt to utilize 
NO’s effects, one of the most promising RSNOs being S-nitroso-N-acetyl penicillamine (SNAP).21-
23  Indeed, our group recently demonstrated SNAP’s ability to release NO over long durations (>3 
weeks) and decrease thrombus formation at localized treatment sites.17 Additionally, Colletta et 
al. recently reported that silicone rubber Foley catheters impregnated with SNAP were able to 
decrease Staphylococcus epidermidis and Proteus mirabilis levels for 2 weeks relative to controls.  
One limitation, however, is that an appreciable amount of SNAP, and likely its dimer, leach from 
the polymers.18  Leaching decreases NO’s efficacy at the localized polymer site and can cause 
NO’s effects at unintended locations within the body.  
Since scientists discovered NO to be the endothelial derived relaxing factor in 1987, 
researchers have continued to synthesize and develop a library of numerous NO donors, each 
bearing characteristics potentially suitable for unique medical applications.21,22  Lipophilic alkyl 
RSNOs have previously been synthesized, however, they have not seriously been considered as 
potential medical sources of NO until recently.24-26  Currently, S-nitroso-tert-dodecyl mercaptan 
(SNTDM) is the most promising alkyl RSNO we have studied to date.  Giles et al demonstrated 
SNTDM’s potential for photoactivated vasorelaxation, however, to the best of our knowledge this 
species has not been studied within polymeric environments.25  SNTDM’s highly lipophilic 
character (LogP=5.31) should increase retention within silicone rubber due to its hydrophobic 
nature.27  As an RSNO’s stability is largely dependent upon the substitution at the site of the 
nitroso functionality, we suspected that SNTDM could provide a long-term NO release.28,29  
Typically, to add NO release to a polymer tubing, it would be desirable to incorporate the 
NO releasing agent into the extrusion process.  However, RSNOs cannot withstand the elevated 
temperature employed for extrusion.18  To overcome this limitation we have adapted our 
recently reported solvent swelling method to impregnate SR tubing with SNTDM, a process which 
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can be conducted at room temperature.  Several solvents have previously been reported to 
effectively swell silicone rubber with no harm to its properties.30  It will be shown here that 
silicone rubber tubing impregnated with SNTDM demonstrates significant NO release duration, 
reasonable storage stability, minimal leaching when in contact with an aqueous phase, as well as 
substantial antimicrobial activity toward S. aureus. 
 
3.2 Experimental 
3.2.1 Materials 
tert-Dodecyl mercaptan (TDM), tert-butyl nitrite (tBuNO2), chloroform (CHCl3), diethyl 
ether (Et2O), dimethyl sulfoxide (DMSO), sodium chloride, potassium chloride, sodium phosphate 
dibasic, potassium phosphate monobasic, ethylenediaminetetraacetic acid (EDTA), copper (II) 
chloride, cysteine, and magnesium sulfate were purchased from Sigma Aldrich (St. Louis, MO).  
Dow Corning RTV 3140 Silicone Rubber (SR) was purchased from Ellsworth Adhesives 
(Germantown, WI).  Standard silicone tubing (1.58 mm I.D, 3.18 mm O.D.) was purchased from 
Helix-Medical (Carpinteria, CA).  All aqueous solutions were prepared with deionized water from 
a MilliQ system (18 MΩ cm−1; Millipore Corp., Billerica, MA).  Phosphate buffered saline (PBS) 
containing 10 mM sodium phosphate, 138 mM NaCl, 2.7 mM KCl, and 100 µM EDTA (pH 7.4) was 
used as the buffer for all in vitro experiments.  Luria Bertani (LB) broth and LB agar were obtained 
from Fisher Scientific Inc. (Pittsburgh, PA). Staphylococcus aureus ATCC 45330 was obtained from 
the American Type Culture Collection. 
 
3.2.2 Synthesis of S-nitroso-tert-dodecyl mercaptan (SNTDM) 
SNTDM was synthesized using a modified version of previously reported methods (see 
Figure 3.1)22,23   tert-Dodecyl mercaptan was dissolved in anhydrous diethyl ether, before adding 
1.1 equivalents of tert-butyl nitrite.  After 45 min of vigorous stirring, the Et2O solution was 
washed with an excess of DI water and then dried with MgSO4. Et2O, residual tBuNO2, and the 
tert-butanol by-product were removed via rotoevaporation to yield a green/red liquid. SNTDM 
could be quantified via its absorbance (CHCl3, ε341=596 M-1cm-1, DMSO ε340=606 M-1cm-1) using a 
Lambda 35 UV-Vis spectrophotometer (Perkin-Elmer, MA). Following synthesis, SNTDM was 
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immediately used for experiments or kept in a -20 ⁰C freezer to be used soon thereafter.  Light 
exposure was minimized during all experiments. 
 
3.2.3 Stimulated SNTDM decomposition  
A 100 W halogen floodlight (GE model 17986) was used as a broad spectrum light source 
to facilitate photo-decomposition of the SNTDM doped materials. The technique was employed 
for various experiments requiring quick conversion to the disulfide and measuring the initial 
amount of RSNO present.  The rate of decomposition was at times also stimulated by addition of 
a 50 mM CuSO4/cysteine solution. DMSO was required as a co-solvent to ensure SNTDM 
solubility.  
3.2.4 UV-Vis spectroscopy  
Following SNTDM’s synthesis, determination of the molar absorptivity at 341 nm (CHCl3) 
and 340 nm (DMSO) allowed the concentration to be determined during subsequent 
experiments.  Pure SNTDM was decomposed via photo-irradiation to form DTDD and the molar 
absorptivity determined to be ε275=418 M-1cm-1 (see Figs. 3.1 & 3.2).  
 
3.2.4 Chemiluminesence NO release measurements  
Samples were placed in a glass sample cell and NO release was measured by a Sievers 
chemiluminescence Nitric Oxide Analyzer (NOA) 280 (Boulder, CO). Conditions varied depending 
on the experiment.  Clear or amber cells were used to control light exposure, and a water bath 
  
Figure 3.1. (a) Nitrosation of tert-dodecyl mercaptan (TDM) to yield S-nitroso-tert-dodecyl 
mercaptan (SNTDM). (b) Decomposition can be catalysed by light, heat, or metal ions such as Cu 
(I) to yield the disulfide and 2 equivalents of nitric oxide (NO). R=C9H19 isomer. 
a) 
b) 
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provided variable temperatures.  If required, the RSNO/SR sample was submerged in PBS 
(pH=7.4, 100 µM EDTA).  NO was purged from the buffer and/or headspace into the detection 
chamber using N2 sweep-gas.  
 
 
3.2.5 Swelling  
Segments of commercial silicone rubber tubing were submerged in vials containing a 
SNTDM/CHCl3 solution. After stirring/soaking in the dark, the pieces were removed, briefly 
rinsed with a lower solubility solvent, dried with a Kim-wipe, placed in clean vials and allowed to 
return to the original length/diameter in the dark before being further drying in a vacuum oven 
in the dark to remove residual CHCl3 (see Figure 3.3).  SR segments were 0.5 cm in length unless 
otherwise specified.  
Loading efficiency:  Tubing segments were impregnated using the swelling method described 
above.  After the tubes had dried, the wt% of impregnated SNTDM was determined by extracting 
the contents of a weighed piece of SR into CHCl3 and measuring SNTDM’s absorbance at 341 nm 
and/or accounting for the total released NO via NOA measurements during stimulated 
decomposition (by photolysis). 
         
Figure 3.2 Spectra displaying the inverse relationship between SNTDM (341 nm) and DTDD (275 
nm) absorbances during decomposition.  
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3.2.6 Characterization of SNDTM/silicone rubber Long term NO release  
Samples were tested on an NOA periodically to determine their average NO release/flux.  
Between measurements, the tubings were soaked in PBS, and stored in a dark 37.5 ⁰C oven to 
simulate physiological conditions.  Prior to each measurement, the soaking solutions were 
replaced with fresh PBS and saved to test for leaching.16  All measurements were conducted in 
triplicate. 
 
3.2.7 Leaching measurements  
PBS soaking solutions were extracted into CHCl3, and the amount of leached RSNO and 
RSSR was determined via UV-Vis spectroscopy.28 All measurements were conducted in triplicate. 
 
3.2.8 Storage stability studies 
 SNTDM impregnated SR tubing storage stability was determined in various environments 
including natural and ambient light, a RT/dark cupboard, 4 ⁰C refrigerator, and in a -20 ⁰C freezer.  
The RSNO levels were monitored periodically via UV/Vis spectroscopy. Stability testing for 
polymeric environments was achieved by first extracting the RSNO/RSSR contents into CHCl3.  
Experiments were conducted in triplicate.  
 
 
3.2.9  Effects of ethylene oxide (EtO) sterilization  
Three cm length silicone rubber tubing segments (1.58 mm I.D, 3.18 mm O.D.) were 
impregnated using the technique described above and submitted to the University of Michigan 
Figure 3.3 SR tubing segments swelling with SNTDM/solvent solution. Tubing retained SNTDM’s 
color upon impregnation with intensity correlating to wt%. The SR tubing return to original 
dimensions following solvent evaporation. 
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Hospital sterilization facility.  During the procedure, the segments were sequentially exposed to 
40-80% humidity for 1 h, EtO gas for 2-3 h (40-80% humidity) followed by exhaust/aeration for 
14 h.  A temperature of 54 ⁰C was maintained during the entire procedure.  The SNTDM content 
of the tubings was measured using UV-Vis before and after sterilization.  The NO flux levels were 
also measured following the procedure.29  
 
3.2.10 Antimicrobial and biofilm study  
Three cm SR tubing pieces were impregnated using the above swelling technique, and the 
open ends were sealed with RTV silicone.  The SR pieces were attached to the coupon holders of 
a CDC biofilm reactor (Biosurface Technologies, Bozeman, MT) using rubber bands. The 
bioreactor was filled with 10% LB broth and injected with 4 ml of overnight grown bacteria (S. 
aureus) culture.  Fresh 10% LB broth was continuously supplied with a flow rate of 100 mL/h via 
a peristaltic pump while maintaining stirring in the bioreactor over the course of the experiment.  
All equipment was autoclaved prior to use and the media reservoir replaced as needed.  The 
bioreactor was kept in a dark 37 ⁰C oven. After 7, 14, and 21 d, the SR tubing segments were 
removed and the portions not touching the rubber bands cut into 2 pieces.  One piece was 
vortexed in 2mL of 10 mM PBS buffer (pH=7.4) to homogenize any biofilm and form a single cell 
bacteria suspension for plating.  The PBS solution was serially diluted, plated on LB agar plate and 
incubated overnight at 37 ⁰C.  The other was stained with Live/Dead BacLight Bacterial Viability 
Kit (Life technologies, Grand Island, NY) to obtain images via fluorescence microscopy (Olympus 
IX71, Center Valley, PA) using Fluorescence Illumination System (X-Cite 120, EXFO), filters for 
SYTO-9 (ex. 488 nm/em. 520 nm), and propidium iodide (ex. 535 nm/em. 617 nm).  Experiments 
were conducted in triplicate.30,31 
 
3.2.11 Statistical Analysis  
Statistical analysis data for all experiments are reported as mean SEM (standard error of 
the mean). Statistical significance between the control and SNTDM impregnated SR catheters 
was determined using a Student’s t-test. Values of p o 0.05 were considered statistically 
significant. 
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3.3 Results and Discussion 
3.3.1 Nitrosation and characterization of SNTDM  
Nitrosation of thiols has found considerable success using acidified nitrite. t-BuNO2 is 
commonly employed for the nitrosation of thiols that are not soluble in aqueous conditions, as it 
readily dissolves in organic solvents, forming a homogeneous solution with the thiol starting 
material. Yields are typically quantitative and require minimal purification. Following nitrosation, 
the byproduct, tert-butanol along with residual tBuNO2 can be removed by room temperature 
rotoevaporation. Their relatively low boiling points do not require higher temperatures that 
would jeopardize RSNO purity and yields.  These conditions proved useful for synthesizing 
SNTDM; however, Et2O was used as the solvent rather than the more common DMSO.  Et2O’s 
low boiling point facilitated removal, which was crucial as neat SNTDM was required for 
subsequent experiments.24,25,34,36 
Given RSNOs’ inherent thermal and photolytic instability coupled with the often lengthy 
preparation times for experiments in this research, being able to determine SNTDM’s 
concentration at various time points was paramount.  The most common way to measure RSNO 
concentrations is by detection of their n0->π* transition (320-360 nm).  Despite this, different 
molar absorption coefficients are frequently reported for the same RSNOs, as determining them 
is difficult due to decomposition during experiments.  For example, extinction coefficients for 
GSNO’s absorbance at 335 nm have been reported as 586, 767, and 922 M-1cm-1.34-40 
Consequently, when determining the molar absorptivity, maximum RSNO purity is 
essential.  The extent of nitrosation was initially determined using chemiluminescence, the 
known gold standard for quantitative NO (and thus RSNO) measurements.39  Immediately 
following purification, a SNTDM/DMSO solution was injected into an NOA cell containing a CuCl2, 
cysteine, water/DMSO solution to facilitate NO release.  ~99.8 +/- 3.5 % of SNTDM was accounted 
for via integration of NO release curves.  This agreed well with UV/Vis measurements that were 
obtained concurrently and showed minimal DTDD to be present following synthesis.  
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Under thermal or photolytic decomposition, RSNOs dimerize to the corresponding 
disulfide.  By starting with pure SNTDM, and shining a 100 W broad spectrum light to induce 
decomposition, we are able to quantitatively convert SNTDM to DTDD (2:1 stoichiometry).17  This 
inverse relationship can readily be monitored by UV-Vis spectroscopy as seen in Figure 3.2. 
Consequently, SNTDM and DTDD concentrations can be rapidly determined which facilitates 
understanding the NO release chemistry, especially the rate of this reaction.   
3.3.2 RSNO Impregnation of Silicone Tubing  
SNTDM has previously shown potential for use as a medicinal NO donor.  Giles et al. 
utilized SNTDM’s photoactivity to controllably induce vasorelaxation and also induce cell death 
in A549 lung carcinoma cells.  However, to date, SNTDM has not yet been studied for use as a NO 
donor in polymeric materials.25,26  After determining suitable methods for RSNO/RSSR 
characterization, we developed conditions to efficiently impregnate SNTDM into silicone rubber, 
as it is one of the most common biomedical polymers and shares a nonpolar character with 
Figure 3.4 Small segments and cross sections of silicone rubber impregnated with (a) 6.8, (b) 4.0, (c) 1.3, 
and (d) 0 % SNTDM showing homogenous dispersions (as indicated by color).   
  
a) b) 
c) d) 
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SNTDM/DTDD, thus increasing retention.  Silicone rubber tubing was impregnated with SNTDM 
via a swelling technique using a CHCl3 solution.  This yielded a translucent green polymer with no 
visible phase separation (see Figure 3.4).  CHCl3 is known to be compatible with PDMS and swell 
the polymer by a 1.39 length ratio.2,30  The tested tubing swelled by the same ratio, and returned 
to their original length following solvent evaporation (Figure 3.3). There was no noticeable 
change to the silicone rubber’s mechanical properties following SNTDM impregnation, but more 
detailed quantitative testing will be required before any definitive conclusions can be made.  
Previously, Bayston et al. impregnated SR with conventional drugs such as rifampicin, 
trimethoprim, and spiramycin using similar swelling conditions with no detriment to the 
polymers’ mechanical properties.41  SNTDM’s homogeneous impregnation can be observed by 
the green color that is visible throughout the length and cross section of the tubing (Figure 3.4).  
This technique provides an effective method for high RSNO loading that is attractive for industrial 
use.18,30,43-45        
Impregnation contrasts with dip-coating, another common method, which results in the 
NO donor being largely concentrated near the polymer’s surface.17  This may yield instability due 
to the RSNO molecules’ close proximity to a higher dielectric solution phase which facilitates 
decomposition and potentially decreases any polymeric “shielding” to light.28 Increased RSNO 
concentration closer to the solution/polymer interface likely encourages leaching as well.  Dip-
coated catheters frequently require top-coats to increase stability and minimize leaching,17 a 
process that increases the catheters’ diameters, potentially making them less suitable for certain 
applications.  With a LogP of 5.31, SNTDM’s lipophilic nature lends itself to swelling in 
hydrophobic polymers, whereas more polar RSNOs like S-nitroso-glutathione and S-nitroso-N-
acetyl-penicillamine have less affinity for hydrophobic polymers such as silicone rubber.17 
Different amounts of SNTDM were impregnated by altering the concentration of SNTDM 
in the soaking solution.  Various soaking solutions with differing concentrations (ranging from 7 
- 150 mg SNTDM/mL CHCl3) were examined (see Figure 3.5).  SR tubing soaked in a 50 mg/mL 
solution resulted in 6.8 wt% impregnation.  These samples provide a NO flux above physiological 
levels for more than 3 weeks and exhibit very low leaching.   
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Tubing with 1.3 and 4.0 wt% SNTDM levels leach SNTDM and the disulphide product at 
only slightly lower rates than the 6.8 wt% loaded SR tubing (see Figure 3.5) and exhibit shorter 
NO release duration.  Therefore, SR tubings impregnated with 6.8 wt% SNTDM were used for the 
majority of subsequent experiments, as they combined low leaching levels with a longer NO 
release duration.  
Figure 3.6 shows the NO release profile for various SR tubing with different wt% SNTDM 
loading during the initial days following preparation and soaking at physiological pH and 
temperature.  All the SNTDM impregnated SR tubings reach a fairly steady-state NO flux after ~10 
min.  This is in contrast with SR impregnated with SNAP, which requires more than 30 min to 
achieve a constant flux.18  The ease of varying the RSNO’s concentration within the polymer 
potentially allows its use for a diverse range of applications. 
 
Figure 3.5 The soaking solutions’ SNTDM concentration affects the amount of impregnation, 
which in turn relates to leaching. The reported leaching levels are the final cumulative 
concentrations corresponding to the SNTDM/SR tubing’s NO release lifetime. 
  
81 
 
3.3.3 Long-term NO Release From SR Tubing 
 
Within blood vessels, the levels of NO produced by endothelial cells never reach the 
surface of IV catheters, etc. owing to the rapid consumption of NO by oxyhemoglobin.  
Consequently, longer term use of polymeric devices is often associated with increased thrombus 
and biofilm formation, leading to a greater risk of an embolism and infection.16,17  By liberating 
NO at their own surfaces, these risks associated with catheter devices can be reduced, allowing 
their extended use.17,18  As shown in Figure 3.7, the SR tubing impregnated with 6.8 wt% SNTDM 
provides an NO flux exceeding or comparable to physiological levels for more 26 d under 
physiological conditions.  RSNOs commonly exhibit a “burst release” of NO, as seen in Figure 3.7 
.  In fact, SNAP impregnated silicone Foley catheters were recently reported to have a 4-fold 
greater NO flux on day 1 than on day 2 (in contrast with SNTDM’s behavior which was less than 
a 2-fold difference).11  This phenomenon doesn’t pose a toxicity concern for intravascular 
catheters since excess NO is rapidly consumed by the surrounding oxyhemoglobin in blood.  
Therefore, an intravascular catheter’s therapeutic window is maximized, accounting for the 
entire duration of NO release (at least 26 days).  Further, NO is not foreign to the urothelium, as 
 
                    
Figure 3.6  Initial NO release in parts per billion (ppb) for SR tubing impregnated with various wt% 
SNTDM (S.A. 0.42 cm2). SNTDM/SR adopts a steady-state flux quickly, taking less than 10 min. 
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it is naturally produced and released by urothelial and other neighbouring cells;46  however, to 
the best of our knowledge, the normal NO flux has not been measured from urothelial cells.  
Consequently, it is not possible to make a direct conclusion regarding the effects of the burst 
release on the urothelium. The effects of long-term exposure to high concentrations of SNAP 
(2.5-5 mM) has been shown to decrease transepithelial resistance; however, following a washout 
of SNAP the effects were reversed.46  In future work, It will be necessary and interesting to 
determine how the levels and duration of NO release affect the urothelial function and integrity. 
 
3.3.4 Leaching Tests  
Many NO donors have been studied within polymers, but leaching remains a significant 
problem for non-covalently bound molecules.17  Leaching decreases the effectiveness of NO 
releasing polymers for localized treatments because the NO donors not retained in the polymer 
will release NO at undesired locations and times.  Seabra et al. improved GSNO’s lifetime by 
dispersing it throughout PVA and PVPD blended films.  Unfortunately, 90% of the GSNO was 
released during the first 24 h when the material was exposed to physiological conditions.47  In the 
case of RSNOs, potentially leached species include the original RSNO and the corresponding 
Figure 3.7 Long-term NO flux for the 6.8wt % loaded SR tubing stored under physiological conditions 
(37 ⁰C, PBS + EDTA buffer, in dark).   
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disulfide, formed within the polymer or in the soaking solution.  Shining a broad spectrum 
halogen light on the soaking solutions can assure complete conversion of any RSNO to RSSR. This 
allowed for the detection of any RSSR to account for all leached species.  In comparing the DTDD 
content with the initial amount of SNTDM impregnated, approximately 2.5% of the impregnated 
RSNO leached from the SR tubing during the 30 d NO release measurements (Figure 3.7).  
Measurements following one day of soaking indicated ~2% had been released.  The larger initial 
release is likely due to the effect of higher water content within the SR polymer phase at the 
outermost surfaces of the material.16,42  Leaching during subsequent days was quite minimal, thus 
requiring the daily soaking solutions to be combined before extraction and concentration in CHCl3 
in order to quantitate the levels of the thiol dimer.  The 2.5% leach rate determined for SNTDM 
from SR over 30 d is much lower than the leaching of SNAP or other RSNO’s reported in similar 
experiments.17,18  SNTDM’s highly lipophilic nature likely accounts for its retention, particularly 
within a lipophilic polymer like silicone rubber which has a 1.2 +/- 0.3 wt% water uptake in the 
bulk of the polymer phase.3  
 
3.3.5 Storage Stability   
 SNTDM’s storage stability was tested under various conditions including as a neat 
material, in solution, and impregnated within silicone rubber.  Tertiary alkyl substitution should 
render SNTDM more stable than other less substituted RSNOs such as S-nitroso-cysteine or 
GSNO, NO donors whose biomedical use has been limited by low stability.28,48  Giles and Kumari 
et al. recently reported on SNTDM’s substantial photoactivity.25,26  Previous research using SNAP 
has found its NO release profile to essentially not be affected by laboratory light (fluorescent).17  
In contrast, the SNTDM in SR samples show a 7-fold increase in flux upon turning on laboratory 
lights.  Additionally, shining light from a 100 W broad spectrum halogen lamp at close proximity 
results in a ~60 fold increase of NO flux, relative to a dark room (see Figure 3.8).  After removing 
light sources, the NO flux returns to the original baseline level. 
General storage stability in the absence of light is another important property of any 
potential NO release medical device.  By incorporating SNTDM into SR tubing, its lifetime can be 
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extended relative to the neat and solution phase samples (see Figure 3.9), however, not to the 
extent to allow the SNTDM-doped SR tubing to be stored in ambient conditions.   
Figure 3.8 SR tubing impregnated with 1.3 wt% SNTDM (S.A.  0.42 cm2) at 22.5 ⁰C in the dark, with 
a) fluorescent light, with b) fluorescent light and a broad spectrum halogen lamp, and again, in 
the c) dark. 
c) 
b) 
a) 
a) 
b) 
Figure 3.9 The effects of light sources and phase dependence on SNTDM’s NO release 
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This is a limitation of the presented system, since SNAP has shown significant stability 
under ambient conditions.  Recently, our group reported ~87% of the SNAP impregnated in SR to 
still be present after 8 months of storage in the dark.11  While SNAP impregnated SR provides 
superior storage stability, one must also keep in mind that the higher levels of RSNO may not be 
beneficial since a larger portion of them will leach from the polymer.  For clinical applications, 
SNTDM impregnated SR devices could be stored in foil packages containing desiccant at reduced 
temperatures to extend their lifetime.  
In contrast with its considerable photoactivity, SNTDM’s tertiary substitution provides 
substantial thermal stability, likely due to the steric hindrance at the site of dimerization.  This 
makes storage in dark environments viable (see Figure 3.10).  SNTDM/SR storage in the freezer 
provided the highest stability with 75% of the initial SNTDM remaining even after 3 months (see  
Figure 3.11).  As expected, SNTDM had a shorter lifetime during refrigerator and cupboard 
storage.  SR’s stabilizing effect was more significant regarding photo induced decomposition 
likely because the disulfide product increased the polymer’s opacity and impeded the 
penetration of incoming light.  SNTDM/SR, neat, and CHCl3 samples were stored in a freezer for 
the duration of their lifetimes.  Within error, no stabilizing effects were observed by SR, nor were 
there statistical differences between the neat and solution phases (see Figure 3.11). 
        
   
   Figure 3.10 SNTDM impregnated SR tubing stored in various environments 
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3.3.5 EtO Sterilization  
Given RSNOs’ thermal or photo-induced decomposition, biomedical devices 
incorporating RSNOs are not suitable to sterilization procedures requiring high heat.  To evaluate 
the SNTDM impregnated SR tubing’s behavior under applicable conditions, we submitted SR 
tubing segments impregnated with several different wt% levels of SNTDM to the University of 
Michigan hospital’s sterilization facility to undergo EtO sterilization.  Following the sterilization 
procedure, the NO flux levels from the samples were measured at different time points (see 
Figure 3.12).  The samples were stored in the dark while submerged in PBS containing EDTA 
between measurements so as to mimic physiological conditions.  All tubing segments exhibited 
NO fluxes above physiological levels for several days, with even the 4 wt% tubings lasting 5 d.  
The 6.8 wt% tubings lasted ~6 d, while the higher concentrations released NO above physiological 
flux for 8 d.  Although care was taken to minimize light exposure, the samples were not sterilized 
immediately following their submission, and several days elapsed before the procedure was 
performed.  Consequently, the SR tubing’s NO release duration would likely be extended were 
this not the case.   
             
 Figure 3.11 Freezer storage for SNTDM in various phases. 
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Despite the reduced SNTDM levels following EtO sterilization, recent work within our 
group has discovered that even lower levels of NO flux (e.g., 0.3 x 10-10 mol cm-2min-1) are able 
to produce substantial antimicrobial effects on silicone rubber surfaces against Pseudomonas 
aeruginosa.  Hence, it is anticipated that the EtO sterilized SNTDM impregnated catheters will 
still have considerable antimicrobial activity despite some loss of active SNTDM during this 
sterilization process.  Other sterilization techniques are also possible and remain to be explored, 
including methods which do not require elevated temperatures such as gamma and 
glutaraldehyde sterilizations. 
 
3.3.6 Anti-biofilm Activity 
 Although biomedical devices are essential for medical care, microbial infections remain 
a serious concern.  Bacteria bear attached to implanted medical devices.  Biofilm formation often 
coincides with this colonization and complicates medical procedures by further increasing the 
risk of infection.  Biofilm formation can decrease the effectiveness of antibiotics and hinder 
opsonophagocytosis, thus leading to chronic infections.49 For bloodstream catheters, if the 
Figure 3.12 Various wt% SNTDM/SR tubing’s NO fluxes following EtO sterilization. 
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devices emit NO at levels similar to endothelial cells, there is zero risk of any toxicity to tissue 
cells, since the liberated NO is immediately scavenged by excess oxyhemoglobin in the blood.  
Therefore, we tested our SNTDM/SR system against Staphylococcus aureus, a microbe 
Periodically, the SR tubing pieces were vortexed in PBS solutions to remove and homogenize 
bacteria/biofilms.  The solutions were serially diluted before plating them on agar. Colonies were 
incubated overnight and then counted.  After 1 week, the NO releasing tubings had 4 orders of 
magnitude less S. aureus relative to controls (see Figure 3.13).  After 14 days, the control bacteria 
levels had remained constant, within error, while the SNTDM/SR tubing had a further reduction 
in amount of live bacteria.  Even after 3 weeks, the SNTDM doped tubings had 3 orders magnitude 
less live bacteria on their surface than the controls, indicating the NO had killed or inhibited 
growth of 99.9% of the bacteria (see Figure 3.13).   The catheters’ outer surfaces were examined 
because they are in more direct contact with the bacterial culture when in the bioreactor. Since 
the NO flux from the catheters’ inner and outer surfaces are equivalent, it is expected that the 
same level of antimicrobial activity will be observed on each surface.  
 
When tubing pieces were removed for cell counting and biofilm testing, pieces were also 
tested via NOA measurements to compare NO flux before and after the CDC experiments 
                    
Figure 3.13  S. aureus levels determined from the SR tubing pieces’ homogenized solution cell 
counts. n=3 for each day. (P < 0.01) 
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 (see Figure 3.14).   Before the CDC experiment, a set of tubing pieces had comparable NO fluxes 
with the oven samples stored at the same temperature.  This also held true for the samples 
measured on days 14 and 21. By the end of the 3rd week, the tubings in the CDC were releasing 
NO below physiological levels (0.33 +/- 0.12 vs. 0.5).  Despite this, they still exhibited a 99.9% 
reduction in live S. aureus bacteria on their surfaces, thus indicating their effective window of 
treatment can potentially extend further than originally expected.  
 
 
 
 
 
 
                                                                         
 
Fig. 3.13 (a) SNTDM impregnated and (b) control silicone rubber tubing images after 7 
days demonstrating NO’s effect at reducing S. aureus levels. (c) SNTDM and (d) control 
tubing images from day 21 indicating difference in biofilm formation.  
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3.4. Conclusions 
 
In summary, S-nitroso-tert-dodecyl mercaptan has been examined for its use as a long-
term NO donor within silicone rubber tubing.  A solvent swelling/impregnation method has 
proven useful for impregnating SNTDM at ranges from 1.3–12.9 wt% within the tubing.  When 
impregnated with 6.8 wt% SNTDM, the tubings exhibit long-term NO release, lasting more than 
3 weeks above the normal physiological flux that occurs at the endothelium/blood interface.  
SNTDM's lipophilicity combined with silicone rubber's hydrophobicity provides a low leaching 
system in which >97% of the original molecule is retained within the polymer after 3 weeks of 
soaking.  Given SNTDM's tertiary substitution, the impregnated SR tubings exhibit reasonable 
stability during storage in a freezer, retaining 75% SNTDM after 3 months.  Due to SNTDM’s 
thermal stability, 7.9 and 10 wt% impregnated SR tubings are able to release NO for 8 d above 
physiological flux levels following EtO sterilization.  This level could likely be increased following 
further optimization.  During a 3-week incubation in a CDC bioreactor, the impregnated tubings 
reduced surface levels of S. aureus by 4 orders of magnitude during the first 2 weeks and 3 orders 
after the third week.  These results confirm the potential for SNTDM impregnated SR materials 
to improve the biocompatibility and antimicrobial activity of medical devices such as urinary and 
Figure 3.14 NO Flux levels measured throughout an antimicrobial experiment compared 
to oven storage. 
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intravascular catheters for at least 3 weeks.  Current efforts are focused on exploring the effect 
of incorporating SNTDM in other biomedical grade polymers, especially with respect to 
photoactivated NO release applications (e.g., to create a source for inhaled NO gas, etc.).  In 
addition, efforts to improve the shelf life of this new NO release polymer using additives to help 
stabilize the NO donor are underway.  Lastly, a proprietary polyurethane from Braintree 
Scientific, Inc. (Braintree, MA) was discovered very recently to have substantial stabilizing effects 
regarding both photolytic and thermal NO release from SNTDM impregnated into this material.  
Therefore, SNTDM's behavior in alternate biomedical polymer matrices warrants considerable 
investigation. 
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CHAPTER 4. 
PHOTOACTIVATED NITRIC OXIDE RELEASE FROM LIPOPHILIC S-NITROSOTHIOLS  
WITHIN BIOMEDICAL GRADE POLYMERS  
 
4. 1 Introduction 
 S-Nitrosothiols (RSNOs) are a class of NO donor that release NO when exposed to light 
and thus have considerable potential for photoactivation therapies.5,6,7  NO’s antimicrobial and 
antithrombotic properties, as well as its ability to kill cancer cells, offer utility for many 
applications such as wound healing patches that prevent infection, or dialysis tubing with  
decreased thrombus formation.  Oplander et al. discovered that shining 420-453 nm light on 
human skin induced NO generation from the inherent S-nitrosoalbumin species.  They proposed 
that this blue light treatment could be therapeutically used to treat hemodynamic disorders 
resulting from impaired bioavailability of NO.8  Previously, Schoenfisch et al. demonstrated that 
upon photoactivation, xerogels modified with an S-nitroso-N-acetylpenicillamine (SNAP) siloxy 
derivatve exhibit a 90% reduction in Pseudomonas aeruginosa adhesion, as well as kill adhered 
bacteria relative to the controls.5   
NO’s role in tumors is not well understood and has in fact been shown to take part in both 
cancer cell progression and death, acting on a survival/anti-apoptotic loop.2  NO synthesis 
pathways are often upregulated in cancer cells and thought to facilitate tumor angiogenesis and 
cell proliferation;1,4 however, the presence of macrophages can increase the local levels of NO 
flux, which provides a cytotoxic effect toward cancer cells.  At high levels, resulting from an 
external source such as a photoactivated RSNO, NO plays an increased role in the generation of 
the ROS, and thus cytotoxicity.  Research has suggested that the inherent presence of NO in 
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tumors promotes their growth and proliferation, however, the additional application of NO  
induces its cytotoxic effects.1  In one study, Rapozzi et al. exposed mice with tumors to 
diethylenetriamine NONOate, a diazeniumdiolate NO donor.  Exposure to the exogenous source 
of NO inhibited the cancer cells’ anti-apoptotic loop, thus facilitating cell death.2 
In this chapter, the photoactivated NO release from two of the exogenous RSNOs 
introduced in Chapter 2, S-nitroso-tert-dodecylmercaptan (SNTDM) and S-
nitrosotriphenylmethanethiol (SNTPMT), as well as S-nitroso-N-acetylpenicillamine (SNAP), is 
examined to identify their behavior in biomedical grade polymers, and determine their potential 
for photoinduced NO releasing medical devices.  SNTDM’s and SNTPMT’s low leaching and 
stability make them viable candidates for such devices, and SNTDM’s photosensitivity provides a 
highly effective and efficient contrast between dark and photoactivated NO release levels. 
 
4.2 Experimental 
4.2.1 Materials 
N-Acetyl-DL-penicillamine (NAP), glutathione, sodium chloride, magnesium sulfate, 
sodium phosphate dibasic, potassium phosphate monobasic, ethylenediaminetetraacetic acid 
(EDTA), tetrahydrofuran (THF), sulfuric acid, diethyl ether (Et2O), N,N-dimethylacetamide 
(DMAc), hexane, chloroform (CHCl3), silica gel, molecular sieves, methanol (MeOH), sodium 
nitrite (NaNO2), t-butylnitrite (t-BuNO2), dodecanethiol (DDT), tert-dodecylmercaptan (TDM), 
tert-butanethiol (TBT), d6-chloroform (CDCl3), dimethylsulfoxide (DMSO), graphite powder (GP), 
and triphenylmethanethiol (TPMT) were purchased from Sigma-Aldrich (St. Louis, MO).  
Hydrochloric acid and sulfuric acid were purchased from Fisher Scientific (Pittsburgh, PA).  
Tecoflex SG-80A (TF), Pellethane 2363-80AE (PELL), and Carbothane PC 3585A were obtained 
from Lubrizol Advanced Materials Inc. (Cleveland, OH).  Dow Corning RTV 3140 Silicone Rubber 
(SR) was purchased from Ellsworth Adhesives (Germantown, WI).  CarboSil 20 90A (CS) was 
obtained from the Polymer Technology Group (Berkeley, CA).  LEDs were purchased from 
LuxeonStar (Brantford, Ontario, Canada), Elast-eon TM E2As (E2As) was purchased from AorTech 
International, PLC (Scoresby, Victoria, Australia).  All aqueous solutions were prepared with 18.2 
MΩ deionized water using a Milli-Q filter (Millipore Corp., Billerica, MA). Phosphate buffered 
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saline (PBS), pH 7.4, containing 138 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, and 100 
µM EDTA was used for all in vitro experiments. 
 
4.2.2 Nitrosation 
TDM and TPMT were nitrosated using excess t-BuNO2 in Et2O, DMSO, THF, or CHCl3 as 
described in Chapter 2, while SNAP’s synthesis used acidified inorganic nitrite in a methanol 
solution.    All nitrosations were performed in the dark at room temperature (RT).  
 
4.2.3 Preparation of RSNO Doped Films 
A known mass of RSNO was dissolved in a THF/polymer solution.  The solution was stirred 
for a few minutes to ensure homogeneity of the film-casting solution composition.   The solutions 
were then cast into Teflon rings on a Teflon plate and dried overnight under a low stream of N2.  
Following solvent evaporation, discs were punched out of the films using a d=0.7 cm hole punch, 
weighed, and if desired for the experiment, dip-coated in a pure 200 mg polymer/4 mL THF 
solution before being dried under vacuum.9    
 
4.2.4 NO Release Measurements 
Nitric oxide was measured using a Sievers chemiluminescence Nitric Oxide Analyzer 
(NOA) 280 (Boulder, CO).  Samples were placed in the sample vessel either neat, dissolved in 
DMSO, or when in films, immersed in PBS (pH 7.4) containing 100 µM EDTA.  Nitrogen was 
bubbled into the solution and any liberated NO was purged and swept from the headspace into 
the chemiluminescence detection chamber of the NOA.  The sample vessels varied depending on 
the experiment, with either clear or amber cells were used to provide control over light exposure.  
If applicable, a DMSO/CuSO4/cysteine solution could be injected to catalyze NO release in 
addition to the photo-irradiation process.  To ensure film samples remain submerged in the 
chamber buffer during experiments, they were impaled on needles and suspended in solution to 
measure NO release rates with the NOA.9,10   All fluxes reported have units of 10-10 mol-cm-2-min-
1. 
4.2.5 Photoactivated NO Release 
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The RSNOs or RSNOs within polymer films were exposed to a light source (100 W halogen 
floodlight (GE model 17986)) at variable distances for photolysis experiments, overhead 
fluorescent ambient light, or on a westward facing windowsill. 
 
4.2.6 Determining the RSNO Levels in Polymer Films 
For initial experiments, the amount of RSNO was determined by stimulating NO release 
from a piece of polymer with a known mass using heat, light, and a Cu(I)/cysteine solution, and 
integrating the NO release curve.  After obtaining the molar absorptivity of compounds, the 
amount of RSNO in a polymer could also be determined by extracting the RSNO content into 
solution (usually CHCl3), or as with the case of soluble polymers, dissolving a known mass (usually 
in THF or DMAc).10  
 
4.2.7 Graphite Powder Topcoat 
 A specific mass (X) of graphite powder was vortexed with a polymer/THF solution 
containing 200 mg-X polymer and 4 mL of THF.   
 
4.3 Results and Discussion 
4.3.1 Polymer Incorporation and Steady-state NO Release  
While the photoinduced NO release from RSNOs is at times a hindrance regarding device storage 
or the duration of treatments, it makes the molecules well suited for photo-controlled 
treatments.  The NO release behavior of RSNOs are, at times, altered when they are incorporated 
into a polymer, with some RSNOs being stabilized in terms of their photo and/or thermal 
decomposition.  Any stabilizing effects are often evident soon after polymer incorporation and 
generally represent themselves with some of the following behaviors:  a) decreased rates of NO 
release; b) more stable NO flux; and c) reduction in the initial burst NO release.  As this chapter’s 
research will demonstrate, different RSNOs respond uniquely to different polymers and stimuli.   
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SNTDM, SNTPMT, and SNAP’s neat phase NO release at RT in the dark was measured and 
is shown in Figure 4.1.  Dissolving the RSNOs in Et2O (SNTDM/SNTPMT) or THF (SNAP) before 
charging them into an NOA cell and then evaporating the solvent via a stream of N2 allowed the 
use of precise amounts of solids otherwise not feasible to dispense with accuracy.  
Decomposition during the process does not occur at a detectable level, as indicated in Chapter 
2.  Each sample was measured < 2 h following purification.  A clear trend is apparent between 
the solid RSNOs, with SNTDM having the greatest thermal release at room temperature from the 
solid state and SNTPMT the least.  Although less so with tertiary species, obtaining a fairly steady 
flux can be difficult.  The phenomenon is inconsistent, with a steady-state NO release obtained 
sometimes more readily than others.  For example, Figure 4.1 shows two samples of equal 
amounts of SNAP crystals that reach the same steady-state after different time periods.  One 
sample required 15 min, while the other only took 1 min.  It appears that the phenomenon does 
not depend on the RSNO’s phase because SNTDM, a liquid, also exhibits this behavior although 
Figure 4.1. Equal amounts of SNTDM, SNTPMT, and SNAP’s (0.5μmol) steady NO flux.  Average 
releases and standard error of the mean are indicated as point values at X=1100 sec.  n=3 
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less frequently.  It also occurs when in polymers, but less so with stable RSNOs such as SNTDM, 
SNTPMT, or SNAP.  Flux is reported as moles x 10-10cm-2min-1.  
 
4.3.2 Silicone Rubber Films Doped with SNTDM, SNTPMT, and SNAP 
NO releases from the RSNO/polymer systems were tested in the absence of light, with 
ambient room light, and with exposure to a 120-watt halogen bulb at 8”.  The NO releases 
between neat and the samples incorporated into the polymers are an indication of any potential 
stability effects provided by the polymeric matrix (see Figures 4.2a-c).  SR did not grant SNTDM 
nor SNTPMT any stabilizing effects in regard to their photoactivity.  In fact, SNTPMT may be 
somewhat destabilized by SR, particularly with respect to photoactivated NO release, although 
further experiments are needed to reduce error and draw a sound conclusion.  Under ambient 
light, the average NO flux from SNTPMT/SR was 20% higher than the neat phase.  It was 25% 
greater in response to a halogen bulb.  In contrast, relative to the neat phase, the SNAP doped 
SR films showed approximately a 13% reduction in NO flux during exposure to ambient light or a 
halogen bulb.  Typically, RSNOs are considerably less sensitive to ambient light than to broad 
spectrum lightbulbs or sunlight.  When incorporated in SR, SNTDM, SNTPMT, and SNAP’s NO 
releases are unique to each species (see Figures 4.2a-c).  SNAP shows a small increase upon 
exposure to ambient light (6.1 ± 0.3 and 6.3 ± 0.4 flux units, respectively), and a more significant 
difference when exposed to broad spectrum light (6.1 ± 0.3 to 13.9 ± 0.4 flux).  Despite SR’s 
potential destabilizing effects on SNTPMT, NO release from the SNTPMT/SR films was actually 
more stable than SNAP in the dark and with the halogen lamp.  For example, when exposed to a 
halogen bulb, SNTPMT films released 11.6 ± 1.0 flux units of NO whereas for SNAP, the flux was 
13.9 ± 0.5.   This is a significant finding considering SNAP is accepted as one of the most stable 
RSNOs.  Again, additional samples will need to be evaluated to more precisely discern their 
differences.   
As observed in Chapters 2 and 3, SNTDM exhibits an uncharacteristically strong response 
to light, both ambient and from a halogen bulb (Figure 4.2a).  The NO fluxes between each species 
in SR are shown in Table 4.1, normalized to the values observed in the dark.  SNDDT is also shown 
to emphasize the rarity of SNTDM’s behavior.  Despite being a structural isomer, with primary 
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alkyl substitution, SNDDT’s sensitivity to light is markedly less.   Exposure to a halogen bulb more 
than tripled its NO flux; nevertheless, this pales in comparison to SNTDM’s change, a 56-fold 
increase. 
Figure 4.2  SR rubber films were doped with 5 wt% of the following RSNOs (a) SNTDM, (b) SNTPMT, 
and (c) SNAP, and the NO release upon exposure to ambient and broad spectrum light compared 
to that from the neat phase (n=3).  Flux values are in units of 10-10 mol-cm-2-min-1. 
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4.3.3 Photoinduced NO Release from Silicone Rubber, CarboSil, E2As, and Tecoflex SG80A 
Doped with SNTDM, SNTPMT, and SNAP   
A polymer’s stabilizing effect in regard to thermolytic NO release does not necessarily 
correspond with photolytic stability (and vice versa).  For the polymer films tested, it seems that 
SNTDM has the greatest photosensitivity in the various matrices where it is the most thermally 
(dark) stable (see Figure 4.3).  For example, SNTDM/SR films have a low NO release in the dark (6 
  Dark Ambient Halogen 
SNTDM 1 5.3 56 
SNDDT 1 1.6 3.4 
SNTPMT 1 1.4 2.2 
SNAP 1 1.1 2.3 
Table 4.1 The normalized flux values depict SNTDM’s extreme response to both ambient and broad 
spectrum light. 
Figure 4.3  SNTDM/SR shows NO release profiles that are unique to specific polymers.  From left to 
right within polymer: the sample was exposed to no light, ambient light, and ambient+halogen 
light, sequentially.  The halogen lamp was turned off in the final sample to demonstrate the rapid 
decrease in NO flux. 
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flux) and a flux of ~540 upon exposure to a halogen light bulb.  When in Tecoflex films, SNTDM 
releases NO at 30 flux in the dark and 485 flux when exposed to a halogen bulb.  Similarly, SNTDM 
has a NO flux of 8 from CS without light and 603 with a halogen light bulb.  In E2As, SNTDM’s very 
high NO flux of 43 in the dark contrasted with a lower one (517) with a halogen bulb.  This trend 
was not observed with SNAP or SNTPMT.  Different RSNO/polymer combinations require 
different times to plateau (if they do).  In Figure 4.3, it can be observed that even under identical 
conditions, SNTDM’s time required to reach maximum flux is very different, depending on the 
polymer.  In SR, SNTDM’s NO release maximizes almost immediately.  This contrasts with SNTDM 
in Tecoflex which required ~18 minutes.  The effects are even more dramatic with SNTPMT (see 
Figure 4.4); for example, in CS, SNTPMT, reaches maximum NO release in under 1 min for ambient 
light and less than 2 min for broad spectrum light.  In Tecoflex, it requires 20 min under ambient 
conditions and 80 min using a halogen bulb (see Figure 4.4).  Some RSNOs do not return to their 
lower level flux for a considerable period of time following light exposure.  During this thesis 
research, it has been consistently observed that films doped with SNTDM return to their lower 
rate of NO release after terminating exposure light as quickly, if not more so, than all other RSNOs 
(data not shown).   
SNTDM’s rapid rates of achieving maximum NO flux values and being able to quickly 
return to baseline fluxes in the absence of light, enhances the use life of the SNTDM-doped films 
as the levels of NO released during times of gradual increase or decrease is not wasted (i.e., would 
not be at target values during these periods).  
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Figure 4.4 SNTPMT reaches maximum flux rapidly while doped in CS, but requires considerably longer in TF. 
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Each RSNO’s flux from the four polymers is shown in Figure 4.5.  Given that SNTDM’s NO 
flux is an order of magnitude greater than SNAP or SMTDM’s, a logarithmic scale is used for the 
y-axes.  SNTDM releases NO at a higher flux than the other RSNOs in all the polymers tested and 
with all the light exposures.  SNTPMT is less sensitive to a halogen bulb than SNAP when in SR, 
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Figure 4.5  5 wt% SNTDM, SNTPMT, and SNAP were incorporated into SR, CS, E2As, and TF and 
their NO flux determined in the dark, with ambient light, and exposed to a halogen bulb.  n=3 
for all measurements of the RSNOs in SR and CS.  For E2As and TF: n=3 for SNTDM, n=1 for 
SNTPMT, and n=1 for SNAP. 
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and comparable in CS. Preliminary studies suggest SNAP is more stable in E2As and TF; however, 
additional trials will need to be performed to confirm this observation.     
 
 
4.3.4 Controlling NO Release: Distance to Light Source 
The NO flux rate during photolytic conditions is directly affected by the distance to the 
light source.  This can also allow control over the amount of NO delivered to patients.  Figure 4.6 
shows the NO release from SNTDM doped SR films in response to a halogen bulb at 4, 8, 12, and 
16 inches distance from the films.  The release increases ~5x between 4 and 16 inches.  
 
 
 
 
4.3.5 Controlling NO Release: Graphite Powder Topcoat 
Figure 4.6  SNTDM/SR’s proximity to a light source affects its rate of NO release.  As the film is moved 
from 4 inches to 16 inches away the rate of NO noticeably decreases. 
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SNTDM’s photosensitivity is excellent for inducing NO release; however, it is so extreme 
that it may be excessive for certain applications and undesirably shorten a device’s lifetime.  
Recently, research has begun exploring the use of graphite powder (GP) topcoats to increase the 
polymers’ opacity and control SNTDM’s photoactivated NO release (see Figure 4.7).  At this point, 
the NO threshold levels required for antimicrobial activity are not known, but effective fluxes 
have been reported.  In Chapter 3, SNTDM killed 99.9% S. aureus successfully with ≥ 0.5 flux NO.  
When SNTDM is incorporated into various polymers its photoactivated NO fluxes often exceed 
this value.   
After applying a 25 wt% GP topcoat, the flux was reduced by half (see Figure 4.8).  
Interestingly, although the photoactivated flux change from light decreased by 50%, the NO 
after release without light (thermal) increased by 100%.  The process could potentially have 
affected the polymer’s water uptake and increased the rate thermal decomposition. 
Figure 4.7  SR films containing SNTDM are dipcoated into a GP/THF slurry and allowed to dry.  
The GP layer diffracts/blocks some light, thus extending the lifetime of the device.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO NO 
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SNTDM’s photoinduced high NO release levels come at the expense of stability during 
storage or routine procedures before treatments.  Consequently, SNTDM can prematurely 
decompose and reduce the efficacy of any devices.  SNTDM/SR/GP samples containing 10 and 25 
wt% topcoats were compared with control samples (no GP topcoats) exposed to ambient light 
(shelf storage) or direct sunlight.  The GP topcoats substantially increased the liftetime of the 
SNTDM/SR films that were exposed to sunlight (See Figure 4.9).  Wherease the SNTDM/SR 
controls had fully decomposed by 3 d, the 10 and 25 wt% SNTDM/SR/GP films lasted 5 and 7 d, 
respectively.  This is likely due to the devices’ increased opacity which reduces light transmission, 
and slows the photolysis of SNTDM.  The films were also stored on a shelf that was exposed to 
ambient light.  The stabilizing effects were again evident, but their effects were less pronounced.  
Also, the 10 and 25 wt% GP/SNTDM/SR films performed very similarily.  The difference in opacity 
may play less a role because being further from the window decreases the photolysis 
decomposition mechanism’s contribution (which the GP helps with).  The intensity of an 
RSNO/polymer’s NO release usually is inversely proportional to its duration.  After an effective 
antimicrobial threshold is determined, decreasing the NO flux to this level (with increased 
graphite powder) will provide the maximum duration of NO release.   
Figure 4.8 The comparative photoresponses of SNTDM/SR with and without a GP topcoat to no 
light, ambient light, and ambient+halogen. Inset is the darkambient light transition. 
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4.4 Conclusions 
SNTDM’s properties are promising for photoactivated NO release applications.  Its 
minimal leaching facilitates localized treatments by conserving levels of the NO donor, and 
prevents the RSNO from entering healthy cells that would otherwise be damaged.  SR, E2As, and 
CS are the most promising polymers that have been tested thus far, as SNTDM is fairly stable 
without external light exposure in these polymers, yet it releases very large amounts of NO upon 
activation with a halogen bulb.  SNAP and SNTPMT also exhibit photoinduced NO release, but at 
substantially lower levels, by more than an order of magnitude in some cases.  Although less 
suitable for photoactivated NO release devices, these studies further elucidated SNTPMT’s 
considerable photolytic stability.  SNTPMT is even more stable than SNAP when incorporated into 
SR and exposed to a halogen light source.  
SNTDM adopts a steady-state NO release more quickly and consistently than many other 
RSNOs, including SNAP.  The phenomenon is observed for both the increased NO release upon 
photactivation and decreased levels following the removal of a light source.  This in combination 
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Figure 4.9  The SNTDM/SR system’s stability, with and without GP topcoats when exposed to 
sunlight and ambient light.  
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with the significant difference between dark and photoactivated NO releases allows more NO to 
be conserved for longer and/or more intense treatments.  Additionally, varying the distance 
between the SNTDM/polymer and the light source provides a straightforward means to control 
the NO release. 
Because SNTDM’s photosensitivity is so extreme, a means to adjust the NO release by 
altering the polymer’s opacity was developed.  Applying a SR topcoat containing graphite powder 
to SNTDM/SR films resulted in a decreased photoactivated release.   The concentration of 
graphite powder can be altered to produce unique NO release profiles.  The GP topcoat reduces 
undesirable decomposition during exposure to ambient light. 
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CHAPTER 5. 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
5.1  Conclusions 
Biomedical devices can increase the risk of infection and thrombosis, both of which are 
serious health concerns.1–3  The research reported in this dissertation prepared and studied a 
number of different lipophilic S-nitrosothiols (RSNOs) for use as controllable sources of nitric 
oxide (NO) to potentially improve the biocompatibility of polymeric medical devices.  The RSNOs’ 
leaching and stability were evaluated in biomedical grade polymers.  Additionally, 
photoactivation, antimicrobial, and antiplatelet studies were performed.  The studies further 
demonstrated the RSNOs’ value as NO-donors.  
In Chapter 2, numerous lipophilic RSNOs were prepared and evaluated as potential NO donor 
candidates.  Several of the RSNOs could easily be ruled out because of their inherent instability, 
which caused preparation and isolation to be detrimental to the amount of available NO.  S-
Nitroso-tert-dodecylmercaptan (SNTDM) and S-nitrosotriphenylmethanethiol (SNTPMT) leached 
minimally from silicone rubber (SR), CarboSil (CS), and Elasteon-E2As, a trait which combined 
with their significant stability made them very promising NO release donors.  Although S-nitroso-
tert-butylthiol (SNTBT) was fairly stable, its significant leaching provided no advantage
over S-nitroso-N-acetylpenicillamine (SNAP), SNTDM, or SNTPMT, thus making it less attractive 
for further studies.   
SNTDM and SNTPMT, when incorporated into SR, E2As, and CS, and exposed to physiological 
conditions, released NO over an extended time period.  SNTDM lasted approximately a month at 
or above physiological flux in each of the polymers, while SNTPMT’s stability provided a 41 d NO 
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flux when in SR or CS.  This duration is unprecedented and promises to prolong the intravascular 
or urinary device’s duration of use by reducing thrombosis or biofilm formation.1,2,6,7  E2As, SR, 
and CS polymers impregnated with SNTDM or SNTPMT were exposed to platelet rich plasma 
(PRP) and demonstrated a significant reduction in platelet adhesion at specific wt%, relative to 
the controls.
 Chapter 3 was based on work recently published in the Journal of Material’s Chemistry B 
(2016, 4, 422-430) involving the development and preparation of SNTDM/silicone rubber 
catheters via a solvent swelling impregnation method.6  Leaching, storage stability, and their 
long-term NO release factors were evaluated and the results indicated that this RSNO system was 
indeed a very promising candidate for improving the biocompatibility of SR catheters.  This was 
further demonstrated by observing a marked reduction in Staphylococcus aureus levels and 
biofilm formation during in vitro studies in a CDC bioreactor.  
Within Chapter 4, experiments examined SNTDM’s and SNTPMT’s photoinduced NO release 
from SR, CS, Tecoflex SG 80A (TF), and E2As and compared them to SNAP.  SNTDM was very 
sensitive to not only broad spectrum light bulbs and direct sunlight, but also demonstrated a 
considerable response to ambient light (in lab fluorescent lighting).  SNTPMT and SNAP, in turn, 
are both stable RSNOs, even when stored under sunlight, broad spectrum bulbs, and laboratory 
light.  SNTDM, SNAP, and SNTPMT in different polymer films provided a wide spectrum of NO 
release rates.   
In addition to the polymers’ effects on SNTDM’s photoactivation, varying the distance to the 
light source proved a simple yet effective way of controlling the NO release.  Lastly, a means to 
alter SR’s opacity using graphite powder was developed and proven to affect the extent of 
photoactivation. 
 Overall, this thesis has provided the first extensive studies regarding the preparation and 
NO release behavior of a series of lipophilic RSNOs.  Particularly noteworthy, SNTDM and 
SNTPMT have properties that may enable them to be useful in developing new NO release 
polymer-based biomedical devices.  They complement one another, as SNTPMT’s stability can 
provide a longer duration of NO release at lower levels, while SNTDM releases more intense NO 
levels for a shorter duration.  Although both exhibit significant platelet reduction relative to the 
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control polymers, SNTDM’s higher NO flux is likely responsible for its even greater antiplatelet 
effects.  Again, this comes as a trade-off, as SNTPMT’s stability better lends itself to device 
storage.  Both demonstrated several advantages compared to SNAP, which is currently one of 
the most promising RSNOs.  They leached dramatically less than SNAP from SR, CS, and E2As.  
SNTPMT films released physiological levels of NO for longer duration than SNAP.  SNTDM’s NO 
release provided superior antiplatelet properties compared to SNAP in each of the tested 
polymers.  As such, this dissertation work has made significant contributions to the rapidly 
growing field of NO releasing biomaterials. 
 
5.2 Future Directions  
SNTDM and SNTPMT are novel for potential use in biomedical devices, and although much 
future work lies ahead before they are ready for clinical studies, their properties lend themselves 
to improving the biocompatibility of biomedical devices.  
As RSNO loading concentrations often vary inversely with the flux, duration of NO release, 
and the leaching, optimal conditions will need to be determined.6  To provide more precise 
measurements and account for any RSSR, an HPLC method needs to be developed.  Any levels of 
RSNO and RSSR that still leach from polymers will need to be tested to confirm their safety for 
medical use.  Wound healing patch applications may tolerate higher levels of leached species 
than intravascular catheters.  If necessary, leaching can likely be reduced via polymer topcoats, 
which has been demonstrated previously to help with similar systems.7,8   
 At this point, the reason for SNTDM’s photosensitivity has not been determined.   The current 
understanding of RSNOs’ stability predicts that SNTDM would be more stable than the primary 
RSNO, SNDDT, in regard to both light and heat activated decomposition.1,6   Other than the 
tertiary alkyl substitution, SNTDM’s structure only differs from SNDDT’s by the methyl groups 
substituted along its backbone, which is consequently shorter (6 vs. 12 carbons).  The RSNOs’ 
alkyl lengths do not directly affect their photosensitivities to the extent observed with SNTDM 
(as demonstrated in Chapter 2).  Consequently, the methyl groups are the predominate structural 
difference.  This variable could be removed by first synthesizing the tertiary thiol via the reactions 
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shown in Figure 5.1.  Reacting 2-undecanone with a methyl Grignard Reagent would yield a 
tertiary alcohol that in turn could be converted to a bromide-leaving group using phosphorous 
tribromide (PBr3).  The bromide-leaving group facilitates an Sn1 substitution with a SH-, thus 
forming the thiol precursor to SNDDT’s tertiary analog, S-nitroso-2-methylundecanethiol 
(SNMUT).  SNMUT and SNDDT will provide a more direct comparison and indicate whether the 
photosensitivity is attributable to the methyl substituents. 
 
 
 
SNTDM’s and SNDDT’s UV-Vis absorbance spectra (see Figure 5.2) only differ minimally in the 
ranges commonly used for RSNO measurements 330-350 nm (ππ*) and 550-650 nm (nN 
π*),10  thus not providing insight into their distinct photosensitivities.  The extinction coefficients 
at SNTDM’s and SNDDT’s λmax (~341nm) are 596 and 522 M-1cm-1, respectively. The most 
distinct difference is the n * transition.  The shoulder of SNDDT’s n * transition is very 
apparent, thus indicating it occurs at a longer wavelength.  This difference also cannot explain 
SNTDM’s greater photosensitivity. 
Figure 5.1 Proposed synthesis of S-nitroso-2-methyl-2-undecanethiol. 
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Figure 5.2 Comparative UV-Vis absorption spectra of 0.7 mM SNTDM and SNDDT. 
 RSNOs are more stable when the C-S-N-O bonds are in the anti-conformation.9  DFT 
calculations have shown that primary RSNOs’ red color and tertiary RSNOs’ green color are due 
to the fact that primary RSNOs exist in the syn conformation while tertiary RSNOs are 
predominately anti.9  SNTDM has exhibited a unique phenomenon in that its green color appears 
to have a slight red shade.  This contrasts with SNAP and SNTPMT which are purely green.  This 
suggests that the syn conformer may play a larger role in SNTDM’s behavior.  An 15N NMR 
experiment would be able to compare the relevant amounts of each conformer.9    
Regarding the NO release from an RSNO, many mechanisms have been proposed and found 
to coexist or be circumstantially dependent.9-11   Scientists commonly assume that both thermal 
and photoinduced NO release occur via homolytic mechanisms;9 however, Singh et al., using ESR 
and a radical trapping agent, determined that only GSNO’s photoactivated NO release generates 
the thiyl radical present in the homolytic NO release.11  SNTDM’s tertiary substitution may offer 
thermal stability by sterically limiting dimerization, however, other structural factors may 
discourage the more stable anti-conformation, and consequently facilitate a photoactivated 
mechanism.  See Figure 5.3 for mechanisms that have previously been proposed.9-11  In Reactions 
5.5 and 5.6, the RSNOs’ tertiary alkyl substitution may hinder dimerization; however, in Reaction 
5.7 the homolytic release of NO would not be impeded by the RSNOs’ substitution.            
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Much of the limitation hindering NO’s use for applications involves its difficulty with 
controllable delivery.  While RSNOs are significantly more stable and easier to use, their thermal 
and photolytic NO release has hindered progress.1,6  At this point, attaining a means for NO 
release only at desired times is one of the ultimate goals for the advancement of RSNOs.6  
SNTPMT’s stability may result in suitable levels of NO release to extend a medical device’s use; 
however, ongoing extended stability studies may indicate that an undesirable amount of 
decomposition still occurs during device storage.  
An additional RSNO, S-nitroso-tris(2,2”,6,6”-tetramethyl-m-terphenyl-5’-yl)methylthiol, may 
ameliorate this problem and is thus worth investigating (see Figure 5.4).  This RSNO has 
previously been synthesized and has demonstrated increased stability (relative to SNTPMT) 
which is attributable to its “bowl-shaped” steric protecting group;12,13 however, its behavior in 
polymers has never been evaluated.  Given its stability and extremely lipophilic character, it may 
be a very promising candidate for improving biomedical devices’ biocompatibilities.   Researchers 
reported low yields following its nitrosation in biphasic conditions (57%)12 which would limit its 
utility.  However, the methods developed in Chapter 2 will likely award greater yields. 
Figure 5.3 Three commonly proposed reaction mechanisms for NO release from RSNOs. 
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 Additionally, a new RSNO/SR system is being developed and studied that utilizes SNTDM’s 
and SNTPMT’s complementary NO release behavior.  SNTDM can provide intermittent and 
intense fluxes of NO, while SNTPMT offers a lower level sustained “maintenance” NO flux.  This 
system could be used in wound healing patches following surgery or injury.  The patches could 
be exposed to light periodically to reduce bacteria as well as promote blood flow, angiogenesis, 
and healing.4,5 
Photodynamic therapy (PDT) is a fairly new medical technique that is currently used in 
ophthalmology, antiviral treatments, oncology, and dermatology.14  PDT uses three components: 
a photosensitizer, oxygen, and light.15  A typical PDT treatment involves administration of the 
photosensitizer, activation by light, and the generation of free radicals.  The radicals are 
transferred to oxygen and form reactive oxygen species (ROS).  The ROS are responsible for the 
cytotoxicity associated with PDT.  Photofrin was the first photosensitizer to gain approval for PDT 
and is registered for use in treating a wide range of cancers.  Despite its effectiveness, patients 
suffer from substantial photosensitivity following PDT.16  Typically, photosensitizers are 
administered intravenously and thus are taken up by all cells.  Eventually, the concentration in 
cancer cells is usually greater; however, optimal selectivity has never been achieved and thus 
normal cells are damaged as well.16   
Figure 5.4 Structure of S-nitroso-tris(2,2”,6,6”-tetramethyl-m-terphenyl-5’-yl)methylthiol.  Its 
lipophilicity and stability make it a promising RSNO worth investigating. 
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SNTDM’s photoactivated NO release may provide a promising alternative to traditional 
PDT.  For accessible tumors, polymeric patches containing SNTDM could provide a localized NO 
release with minimal damage to healthy tissue (unlike with systemic photosensitizers).  Frost et 
al. proposed that fiber optic catheters containing an RSNO can be used to reach otherwise 
inaccessible treatment locations.17  SNTDM is well suited for such an application.  Recently, 
scientists have begun using light emitting diodes (LEDs) of different wavelengths to produce 
different NO release profiles.  Gierke et al. demonstrated that 470 nm LED effectively releases 
NO from a SNAP-cyclam derivative.17  Dungel et al. used the same LEDs to induce NO release from 
nitrosyl hemoglobin in order to induce angiogenesis.18  
Given its promising photosensitivity, SNTDM in SR polymer was exposed to blue (470 nm) 
and green (530 nm) LEDs and compared to a 100 W halogen bulb (see Fig. 5.5).  This resulted in 
three distinct NO release profiles.  The green LED caused a low NO release (20 ppb) that 
plateaued quickly and maintained a steady release over the duration of the experiment.  The blue 
LED caused the most intense NO release and did not plateau.  The halogen light induced an NO 
release that was essentially a compromise between the green and blue light values.  These three 
unique profiles could provide different treatment options.  For example, procedures requiring a 
shorter and more intense NO release would use a blue light to activate SNTDM.  These 
experiments comparing the effects of blue LED, green LED, and halogen bulbs are merely 
Figure 5.5  Exposing SNTDM to a green or blue LED, or halogen bulb results in three drastically 
different NO release profiles.  
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preliminary.  To fully understand SNTDM’s behavior and develop a correlation between light 
source and NO release profile, the lights’ intensities will need to be adjusted to comparable 
levels.  A pulse width modulator could be used for this purpose.19  
 
 
 
 
 
 
 
 
5.3 References 
1 E. J. Brisbois, R. P. Davis, A. M. Jones, T. C. Major, R. H. Bartlett, M. E. Meyerhoff and H. 
Handa, J. Mater. Chem. B, 2015, 3, 1639–1645. 
2 A. Colletta, J. Wu, Y. Wo, M. Kappler, H. Chen, C. Xi and M. E. Meyerhoff, ACS Biomater. 
Sci. Eng., 2015, 1, 416–424. 
3 Y. Onuki, U. Bhardwaj, F. Papadimitrakopoulos and D. J. Burgess, J. diabetes Sci. Technol., 
2008, 2, 1003–1015. 
4 M. Neidrauer, U. K. Ercan, A. Bhattacharyya, J. Samuels, J. Sedlak, R. Trikha, K. A. Barbee, 
M. S. Weingarten and S. G. Joshi, J. Med. Microbiol., 2014, 63, 203–9. 
5 C. Tison, http://lunainc.com/wp-content/uploads/2014/04/NO-White-Paper-August-
2013.pdf, accessed 7-29-2016. 
6 A. R. Ketchum, M. P. Kappler, J. Wu, C. Xi and M. E. Meyerhoff, J. Mater. Chem. B, 2016. 
7 Y. Wo, Z. Li, E. J. Brisbois, A. Colletta, J. Wu, T. C. Major, C. Xi, R. H. Bartlett, A. J. Matzger 
and M. E. Meyerhoff, 2015. 
120 
 
8 J. M. Joslin, S. M. Lantvit and M. M. Reynolds, ACS Appl. Mater. Interfaces, 2013, 5, 9285–
94. 
9  P. R. McCarren; Computational Investigations of Organometallic and S-Nitrosothiol 
Reaction Mechanisms, 2009, pp 102-133 UCLA, Los Angeles.   
10 D. L. Williams; Nitrosation Reactions and the Chemistry of Nitric Oxide, Elsevier, 
Amsterdam, 2004. 
11 R. J. Singh, J. Biol. Chem., 1996, 271, 18596-18603. 
12 K. Goto, Tetrahedron Letters, 2000, 41, 8479-8483. 
13 T. C. Harrop, J. Am. Chem. Soc, 2008, 130, 15602-15610. 
14 K. J. Reeves, M. W. R. Reed and N. J. Brown, J. Photochem. Photobiol. B Biol., 2009, 95, 
141–147. 
15 V. Rapozzi, E. Della Pietra, S. Zorzet, M. Zacchigna, B. Bonavida and L. E. Xodo, Nitric 
Oxide, 2013, 30, 26–35. 
16 L. B. Josefsen and R. W. Boyle, Met. Based. Drugs, 2008, 2008, 276109. 
17 G. E. Gierke, M. Nielsen, M. C. Frost, Sci. Technol. Adv. Mater, 2011, 12, art. #55007–5. 
18 P. Dungel, J. Hartinger, S. Chaudary, P. Slezak, A. Hofmann, T. Hausner, M. Strassl, E. 
Wintner, H. Redl and R. Mittermayr, Lasers Surg. Med., 2014, 46, 773–80. 
19 K. Szolusha, LT J. Analog Innov., 2012, 34-35. 
 
 
 
 
121 
 
APPENDIX A 
Synthesis, Spectroscopy, and Stability of the Nitric 
Oxide Donor S-Nitroso-N-acetylpenicillamine: An 
Undergraduate Laboratory Experiment 
Alex R. Ketchum1, Alexander K. Wolf1, Mark E. Meyerhoff1* 
1Department of Chemistry, University of Michigan, Ann Arbor, 48109, USA 
*Corresponding author 
 
 
Abstract  In the following experiment, organic chemistry students will gain hands-on experience 
with ultraviolet-visible spectroscopy and 1HNMR spectrometry after synthesizing S-nitroso-N-
acetyl-D-penicillamine (SNAP).  SNAP is a popular small nitric oxide (NO) donor that has shown 
considerable promise for biomedical applications.  Our group has consistently demonstrated that 
polymers such as silicone rubber or polyurethanes containing SNAP can release NO and use its 
antithrombotic and antimicrobial properties to prevent clot and bacteria biofilm formation.  
Following the straightforward acid catalyzed synthesis, students will characterize the product 
with 1HNMR.  Studying SNAP’s HNMR spectrum provides students with an opportunity to 
experience and learn many important concepts including chemical shifts, integration, topicity, 
multiplicity, and coupling constants.  Students will also calculate SNAP’s molar absorptivity using 
UV-Vis spectroscopy and use it to monitor the compound’s stability in various environments.  The 
experiment is presented in a manner most appropriate for an undergraduate second semester 
organic laboratory course; however, it can be readily tailored to first semester students by 
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omitting the 1HNMR portion.  The stability tests are suitable for various environments and 
durations, allowing the experiment to be used for single or multiple class periods if desired. 
A.1 Introduction 
1HNMR spectrometry is a synthetic chemist's most powerful and common tool for 
characterizing and studying a molecule’s structure and behavior.  Additionally, UV-Vis 
spectroscopy is ubiquitous throughout many fields within the scientific community, ranging from 
organic, inorganic, analytical, materials science, and biochemistry.  It can be used to identify 
molecules, observe reactions, and quantify molecular species [1-3].  Students with experience 
using these methods/instrumentation are likely to be better prepared and more competitive for 
entering graduate school or starting an industrial position.  In this undergraduate experiment, 
students will synthesize an S-nitrosothiol (RSNO), S-nitroso-N-acetylpenicillamine (SNAP), and 
use these spectroscopic and analytical techniques to characterize and test its stability in various 
environments (Figure A.1).  
 
 
RSNOs are a class of molecules containing a nitrosonium group bound to the sulfur on a 
thiol molecule.  There are three known endogenous RSNOs, S-nitrosocysteine, S-
nitrosoglutathione, and S-nitrosoalbumin, each of which functions as a nitric oxide (NO) donor 
[4].  In the 1980’s, scientists identified NO as the “endothelium derived relaxing factor,” due to 
the fact that it is released by the endothelium and promotes smooth muscle relaxation 
(controlling blood pressure).  After this discovery, NO has been found to also have important 
 Figure A.1. Synthesis of S-nitroso-N-acetylpenicillamine via the nitrosation of N-
acetylpenicillamine using acidified nitrite. 
  
(rxn. A.1) 
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antithrombotic and immunological roles, and serve as a signaling molecule for many biological 
functions [4-6].  Considerable research time and funding has been committed to thoroughly 
understanding and utilizing its properties for medical applications [4,5].  NO is unique in that it is 
a gaseous radical-bearing molecule, which is the reason for much of its reactivity.  NO is rapidly 
oxidized to nitrogen dioxide upon exposure to oxygen.  Endogenously, it reacts with 
oxyhemoglobin to form methemoglobin.  These reactions are responsible for NO’s brief half-life 
of only a few seconds in blood.  Consequently, scientists looking to use NO for medical 
applications currently study NO donors, such as SNAP, with the goal of creating stable and 
controllable NO release sources [4-8].  
Although SNAP is to date one of the most stable RSNOs, it still is susceptible to 
decomposition during preparation and storage under some conditions.  RSNOs release NO via 
thermal or photolytic activation—stimuli which are difficult to avoid (Reaction 1).  Consequently, 
considerable research has focused on determining the stability of SNAP and other RSNOs in 
various environments so as to determine their suitability for biomedical applications [9,10].   
  
                                                 2 RSNO  RSSR + 2 NO                                                            (rxn A.2)                                   
 
In today’s world, health or medical applications are often at the forefront of scientific 
research.  Areas such as medicinal chemistry, pharmaceutical science, and materials science are 
highly interdisciplinary as they frequently involve synthetic, analytical, and spectroscopic 
techniques [1,3,11-13].  Following the synthesis of this biologically-relevant molecule, students 
will perform analytical tests similar to those that are commonly used with SNAP or other NO 
donors during professional research [9,10].  Students will nitrosate the thiol precursor, N-acetyl-
D-pencillamine (NAP), in an aqueous/methanolic solution using acidified nitrite [6,9,10,14].  
Reaction vessels should be covered in aluminum foil to minimize decomposition from exposure 
to light.   Primary RSNOs are red in color; however, tertiary RSNOs such as SNAP are typically 
green.  Consequently, students can visualize the nitrosation via the appearance of the green color 
(Fig. A.1).  In turn, as NO is released, SNAP decomposes into its corresponding disulfide, and loses 
its color, reverting to an off white solid (the disulfide of NAP) (Fig. A.2).  After the reaction to 
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prepare SNAP has reached completion, students can separate the SNAP crystals via vacuum 
filtration and confirm SNAP’s identity via 1HNMR spectroscopy using d6-DMSO as the solvent.  
SNAP can be detected and the nitrosation conversion quantified using UV-Vis spectroscopy.  
RSNOs’ strong nπ* absorptions between 320-360 nm allow straightforward and accurate 
measurements. SNAP’s molar absorptivity coefficient has been reported as ε340=1075 M-1cm-1 in 
water; however, this experiment provides an opportunity for students to learn about the Beer-
Lambert Law (Eq. A.2) by determining the molar absorptivity coefficient and using it to measure 
SNAP’s stability [9,10,14].  The Beer-Lambert Law is fundamental to UV-Vis spectroscopy, thus 
making it a critical skill for students to master in their studies and eventually apply in almost any 
scientific research field.  
 
                 Absorbance = ε·l·C                                          (eq. A.1) 
    
A.2  Experimental 
A.2.1. Materials and Methods:  
N-Acetylpenicillamine, deuterated dimethyl sulfoxide, sodium nitrite, 
ethylenediaminetetraacetic acid (EDTA), potassium chloride, sodium phosphate dibasic, 
potassium phosphate monobasic, and methanol were purchased from Sigma-Aldrich (St. Louis, 
 
Figure A.2. SNAP decomposes to form the corresponding disulfide (RSSR) and NO.  Positions are numbered as 
references for Figures 3, 4, 5, and Table 1. 
  
(rxn. A.3) 
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MO).  Concentrated hydrochloric and sulfuric acids were products of Fisher Scientific (Pittsburgh, 
PA).  Aluminum foil was purchased from Meijer (Ann Arbor, MI).  Calculations were performed 
using Microsoft Excel (version 10).  UV-Vis measurements were obtained using a Lambda 35 UV-
Vis spectrophotometer (Perkin-Elmer, MA).  1HNMR spectroscopy was performed using a Varian 
400 MHz spectrometer and the data processed using MestReNova.  pH 7.4 phosphate buffered 
saline (PBS), containing 10 mM sodium phosphate, 138 mM NaCl, 2.7 mM KCl, and 100 µM EDTA 
was prepared using DI water. Depending on the experience level of the students, the PBS buffer 
and acidic stock solutions can be prepared in advance by staff.  All reagents used are relatively 
inexpensive, further facilitating the adaptation of this experiment for an undergraduate class. 
 
A.2.2. SNAP Synthesis:  
SNAP was synthesized using a modified version of previously reported methods 
[9,10,13,14].  18 mL of 1:1 v/v MeOH/1M HCl(aq) solution containing 1 mL of conc. H2SO4 was 
prepared and poured into a 50 mL RB flask containing 1.0 g NAP (5.2 mmoles) and a stir-bar. 
Following dissolution, which required vigorous stirring, the flask was covered with aluminum foil 
and charged with 0.71 g NaNO2 dissolved in 10 mL DI water over the course of 5 min.  The 
aluminum foil can be briefly peeled back to observe the green color change corresponding with 
the appearance of SNAP.  After 45 min of stirring, the solution was chilled on ice and the SNAP 
precipitate was isolated via filtration. SNAP crystals were spread over a Buchner funnel’s filter 
paper to maximize surface coverage.  Crystals were rinsed with ice cold water to remove salt 
byproducts and then subsequently with acetone previously chilled in an ice bath [9,10].  Finally, 
the SNAP crystals were briefly rinsed with ice cold diethyl ether to remove acetone and facilitate 
drying.  The SNAP crystals were scraped into a beaker and spread out to maximize surface area 
before drying under a low stream of N2.  Crystals were weighed to determine yield, taking care 
to minimize light exposure.  
 
A.2.3. Proton Magnetic Resonance (1HNMR) Spectroscopy: 
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Spectra were obtained in d6-DMSO and shifts identified were referenced to DMSO’s 
resonance at 2.5 ppb.  Peaks were picked, coupling constants measured, and the integration 
determined.   
 
A.2.4. Molar Absorptivity:  
The molar absorptivity was determined for SNAP following synthesis.  Solutions of 0.80, 0.50, and 
0.25 mM of SNAP in PBS buffer were prepared for UV-Vis measurements.  Students should be 
sparing when making samples to conserve SNAP for subsequent spectroscopic measurements.  
After testing each sample, a calibration curve was determined using Microsoft Excel using the 
absorbance values at 340 nm wavelength.  The 0.80 mM SNAP solution was used for further 
stability studies.  
 
A.2.5. Stability Studies 
The 0.80 mM SNAP(PBS) samples were prepared in 20 mL vials using PBS buffer with EDTA 
present and exposed to varying degrees of heat and light.  Exposure conditions can vary and be 
tailored to the number of students, and access to available light sources, e.g. windows, 
fluorescent lights, etc.  Samples were placed on a window sill and in a hood, cupboard, and 
refrigerator [10] to provide a variety of thermal and light exposures.  Samples were also covered 
in a dark 37 ⁰C oven to simulate physiological conditions.  Each sample’s RSNO concentration was 
tested via UV-Vis spectroscopy at regular intervals.  The vials were immediately returned to their 
appropriate storage conditions following measurements.  Absorbances at 340 nm were recorded 
and used to calculate remaining SNAP levels, which were in turn plotted over time to exhibit the 
varying effects of the stimuli [10].  The time intervals are flexible and can be modified to allow 
for variation in class duration and frequencies. 
 
A.3. Results and Discussion 
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A.3.1. SNAP Synthesis 
Although nitrosation is commonly a quantitative reaction, the workup causes some 
product to be lost in the process due to SNAP’s partial solubility in both water and acetone.  We 
obtained 36 ± 5% yields for n=3 preparations.  Assuming the procedure is accurately followed, 
and the molar absorptivities are calculated soon following the synthesis (to minimize sample 
decomposition), students should obtain molar extinction coefficients close to the reported value, 
ε340=1075 M-1cm-1 [9].  If instrumentation is limited, SNAP samples can be stored in a cupboard 
or refrigerator to prolong lifetimes.  Since the reaction is quite reproducible, some students can 
determine the molar absorptivity prior to performing 1HNMR spectroscopy if necessary.  As long 
as samples are stored in the dark at or below room temperature, negligible decomposition will 
occur during the processes [10].  
 
A.3.2. 1HNMR Spectrometry  
SNAP’s 1HNMR spectrum was taken following synthesis and is displayed in Figure A.3a.  
The peaks are numbered as shown in Figure A.2, with the corresponding proton shifts detailed in 
Table 1.  At this point minimal disulfide is present, allowing easy and accurate characterization.  
SNAP’s synthesis is easily integrated within undergraduate curriculum as the reaction is reliably 
quantitative, and consequently has minimal residual starting material that would otherwise 
convolute the spectra [9,10,14].  There is minimal overlap of shifts and the integration aligns well 
between SNAP’s protons.  The N-H and adjacent C-H protons at positions 2 and 3, respectively, 
are distinct, and this serves as an opportunity for students to determine the coupling constants.  
These protons also work superbly for comparing SNAP:RSSR concentrations during 
decomposition, as they too are distinct (Fig. A.4).  Due to inherent chirality, the protons at 
positions 4 and 5 in SNAP and 10 and 11 in the corresponding disulfide are diastereotopic.  The 
resulting upfield resonances are useful traits for teaching students about topicity (See Figure 
A.5b).  
An intermediate spectrum was obtained following partial SNAP decomposition so as to 
demonstrate the SNAP:RSSR proton resonances relative to each other.  The amide and 
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neighboring C-H proton shifts can be integrated to compare concentrations.  RSNOs’ 2:1 
stoichiometric decomposition must be taken into account when comparing the relative 
composition of each species.  Protons at positions 3 and 9 serve as integration comparisons due 
to their aprotic nature.  In Figure A.4b, 0.54/(0.54+1.00/2) = 52% of SNAP remains.  If time is 
available, students can take spectra during and/or following decomposition to compare SNAP 
and the dimer’s coupling constants: 9.4 and 8.8 Hz, respectively.  Finally, Figures A.3c, A.4c, and 
A.5 display the dimer following decomposition. 
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Figure A.4. Close-up of the pair of doublets corresponding to SNAP’s N-H and C-H at positions 2 and 3, respectively, as 
well as the corresponding disulfide protons at positions 8 and 9.  Integration is referenced to the C-H at position 3 and 9 of 
SNAP and the disulfide, respectively.  Spectra correspond with a) pure SNAP, b) partially decomposed SNAP, and the c) 
disulfide product. 
Figure A.5.  Expanded region showing SNAP and the 
disulfide’s a) carboxylic acid b) methyl protons. 
  
  
a) 
b) 
Table A.1. Proton shifts, splitting, and coupling 
constants for SNAP (1-6), and the RSSR (7-12) 
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A.3.3. UV-Vis Spectroscopy 
RSNOs absorb light in the visible range; however, this absorption is considerably weaker 
than typically observed for organic molecules in the ultraviolet region.  Nonetheless, we 
determined SNAP’s molar absorptivities to be ε340=1079 M-1cm-1 and ε591=17.3 M-1cm-1.  This 
agrees well with the recently reported value, ε340=1075 M-1cm-1.   The corresponding spectra and 
calibration curves are shown in Fig. A.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. a) UV-Vis spectrum of SNAP at 3 different 
concentrations. The absorbance at 340 nm was subsequently 
used to determine the molar absorptivity as shown in the 
calibration curve (b). 
a) 
b) 
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3.4. Stability 
 
We tested the SNAP solutions for 4 days in a range of different conditions (Figs. A.7 and 
A.8); however, this variety is not required for a successful experiment.  The most useful 
conditions for drawing comparisons would be those separately displaying the effects of 
temperature and light; i.e. a combination of available dark environments: covered vial in a 
cupboard/refrigerator/37 oC oven, and separately: windowsill/hood/cupboard, to observe the 
effects of light.  It is worth noting that the observed stabilities are circumstantially dependent, 
and the students’ SNAP concentrations may differ from ours due to factors such as room 
temperature, distance from windows, and cloud cover.  The significance lies in the results relative 
to one another.  Photolytic decomposition can be observed in as little as 30 min, with 12, 6, and 
2% SNAP lost for window, hood, and cupboard samples, respectively.  The rapid photolytic 
decomposition allows the experiment to be concluded within a single class period, if desired. The 
effects of light on NO release become increasingly apparent during subsequent measurements.  
After 2 h, 5% of SNAP had decomposed for samples at room temperature that were not exposed 
to the light (cupboard), compared to 9% with the hood samples.  SNAP solutions exposed to 
direct sunlight had lost 21% by the 2 h timepoint.  The samples with direct light exposure had 
Fig.A.7 
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fully decomposed to the disulfide after 2.5 days.  Students should readily be able to conclude that 
light exposure stimulates NO release. 
SNAP is more stable with regard to the tested temperature range (Fig. A.8).  Appoximately 
6% of the SNAP had decomposed from the 37 ⁰C samples after 30 min, while 2 and 0% had been 
lost from the cupboard and refrigerator, respectively.  After 2 h, 83, 95, and 97% SNAP remained 
in the oven, cupboard, refrigerator respectively.  The distinct SNAP concentrations facilitate the 
students’ abilities to draw a conclusion regarding the effects of temperature on NO release.  The 
oven, cupboard, and refrigerator samples had released all their NO after approximately 1, 2.5, 
and 3.5 days.  Additional data points, as well as optionally monitoring the decomposition with 
1HNMR, allows the stability study to be extended for subsequent class periods if so desired.  
A.4. Conclusions                                  
The experiment described herein provides an opportunity for undergraduate chemistry 
students to develop and strengthen several crucial skills that are applicable in many scientific 
fields [1-3,9-11].  Students will gain valuable experience using a UV-Vis spectrometer and learn 
about the Beer-Lambert Law by determining SNAP’s molar absorptivity.  In d6-DMSO, SNAP’s 
structure is inherently useful for gaining experience with 1HNMR spectrometry.  In addition to 
measuring SNAP’s proton resonances and integrations, students can investigate spectroscopic 
topics including multiplicity and coupling constants.  Testing the molecule’s stability places 
 
Figure 8. 0.8 mM SNAP (aq) solutions exposed to varying degrees of heat while stored in 4 different locations.  The inset is the initial 6 h 
expanded. 
 
Fig.A.8 
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students within a model that closely simulates industrial chemistry research, as they witness 
firsthand the relevance of stability for potential products. [9,10].  Indeed, SNAP and other RSNOs 
are being examined as NO donors to develop a new generation of thromboresitant and 
antimicrobial intravascular and urinary catheters, etc. [9,10]. 
     RSNOs are rarely included, and thus critically underutilized, in undergraduate organic lectures 
and laboratories despite their popularity and significance in current biomedical research.  This 
experiment is applicable in a wide range of laboratory settings, allowing variation for the number 
of students, experience levels, desired experimental duration, and available instrumentation.  
Due to SNAP’s useful properties, it provides a simple addition to any curriculum to expand upon 
thiol or disulfide chemistry, while allowing students to practice using two of the most important 
scientific instruments in chemistry [1-3].   
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